key: cord-0714323-6svtqk11
authors: Pecson, Brian M.; Darby, Emily; Haas, Charles N.; Amha, Yamrot M.; Bartolo, Mitchel; Danielson, Richard; Dearborn, Yeggie; Di Giovanni, George; Ferguson, Christobel; Fevig, Stephanie; Gaddis, Erica; Gray, Donald; Lukasik, George; Mull, Bonnie; Olivas, Liana; Olivieri, Adam; Qu, Yan
title: Reproducibility and sensitivity of 36 methods to quantify the SARS-CoV-2 genetic signal in raw wastewater: findings from an interlaboratory methods evaluation in the U.S.
date: 2021-01-20
journal: Environ Sci (Camb)
DOI: 10.1039/d0ew00946f
sha: ed97232d5903109b1058ab07229de857398482c7
doc_id: 714323
cord_uid: 6svtqk11

In response to COVID-19, the international water community rapidly developed methods to quantify the SARS-CoV-2 genetic signal in untreated wastewater. Wastewater surveillance using such methods has the potential to complement clinical testing in assessing community health. This interlaboratory assessment evaluated the reproducibility and sensitivity of 36 standard operating procedures (SOPs), divided into eight method groups based on sample concentration approach and whether solids were removed. Two raw wastewater samples were collected in August 2020, amended with a matrix spike (betacoronavirus OC43), and distributed to 32 laboratories across the U.S. Replicate samples analyzed in accordance with the project’s quality assurance plan showed high reproducibility across the 36 SOPs: 80% of the recovery-corrected results fell within a band of ±1.15 log(10) genome copies per L with higher reproducibility observed within a single SOP (standard deviation of 0.13 log(10)). The inclusion of a solids removal step and the selection of a concentration method did not show a clear, systematic impact on the recovery-corrected results. Other methodological variations (e.g., pasteurization, primer set selection, and use of RT-qPCR or RT-dPCR platforms) generally resulted in small differences compared to other sources of variability. These findings suggest that a variety of methods are capable of producing reproducible results, though the same SOP or laboratory should be selected to track SARS-CoV-2 trends at a given facility. The methods showed a 7 log(10) range of recovery efficiency and limit of detection highlighting the importance of recovery correction and the need to consider method sensitivity when selecting methods for wastewater surveillance.

The average log-difference between the measured SARS-CoV-2 concentrations and the theoretical LOD for each SOP is shown in 0 (below limit of detection) 0 (below limit of detection) 1S.3H 0 (below limit of detection) 0 (below limit of detection) 2. 1 1.2 0 (below limit of detection) 2.2 0.4 0.4 2. 3 1.0 0.5 2S.1 0 (below limit of detection) 0 (below limit of detection) 2S.2 0.2 0 (below limit of detection) 2S. 3 1. 7 1.9 0.3 4S.8 0 (below limit of detection) 0 (below limit of detection) 4S.8H 0 (below limit of detection) 0 (below limit of detection)

The uncorrected SARS-CoV-2 concentrations (N1 target) and OC43 recovery efficiency for the SOPs that evaluated the impact of heat pasteurization are shown in Figure 

Labs were not required to share their SOPs publicly in order to participate in the study, though full SOPs were shared with the project team. Nearly all of the labs agreed to share their detailed SOPs for this publication and are provided in the Electronic Supplementary Information. The SOPs provided here cover each of the eight major method groups described in the manuscript.

1. For each sample three replicate extractions will be performed (i.e. three for the SJCe influent and three for the JWPCP influent). The Quick-RNA Fecal/Soil microbe microprep kit (Zymo Research Cat. R2040) is used for the RNA extractions. 2. For each extraction, take the tubes out of the -80 o C freezer and thaw them in the BSC (class II B2) in Virology B lab. 3. Two mock extractions will be performed with each batch. One with extraction control RNA (in vitro transcribed AdV IPC RNA) and one without the extraction control RNA. a. The first will have 240µL of DEPC water and 750µL of RNA shield. The other 10µL will be carrier RNA (Qiagen Cat. 1068337 ). b. The second will have 235µL of DEPC water and 750µL of RNA shield. The remaining volume will be the carrier RNA (10µL) and the AdV IPC extraction control RNA (5µL). 4. For each tube, place the entire volume (about 1 mL) into a bead bashing tube from the Zymo Quick-RNA fecal/soil kit (cat. R2040). There should be eight tubes in total. 5. Bead beat on the FastPrep24 homogenizer for 40 seconds at 6m/s. 6 . To get rid of the foam after bead beating, spin the samples down in the refrigerated microcentrifuge in the Virology B lab set at 4 o C. Spin at >12,000 x g for 5-7 minutes. Note the Zymo protocol says to spin for one minute, this was found to be insufficient to get rid of the foam. 7. After centrifugation, remove the supernatant and place in a clean microfuge tube then add 5 µL of the in vitro transcribed AdV IPC RNA (approximately 10 4 copies/µL, usually a -7 dilution) to each sample tube and to the one mock extraction tube containing 230µL of DEPC water. This can be added directly after the sample is transferred to the new tube. a. The remaining mock extraction tube does not get the AdV IPC RNA and serves as another negative extraction control. SOP 1.1 2 8. To the two mock extraction tubes (one with extraction control RNA and one without) add 10 µL of carrier RNA diluted to 1ug/ul (Qiagen cat. 1068337). 9 . Proceed with the Zymo extraction as stated in the instructions. a. Note that in step 4 of the Zymo protocol it states to transfer 400µL of supernatant to a new tube. The extraction volume we have is more than 400µL (usually around 700µL). We pipette a fixed volume of 700µL and place it in a sterile 2 mL tube then add an equal volume of RNA binding buffer (700µL) from the Zymo kit as stated in the Zymo kit's instruction notes. b. The total volume is processed through one Zymo-Spin IIICG Column as stated in step 5 of the Zymo protocol (around 1.4mL). This will require multiple spins to get the entire volume through. Collect and save each of the supernatants from the spins. Combine all of the supernatants in a sterile 15 mL conical tube and add one volume of ethanol (approximately 1.4 mL) as stated in step 6 of the protocol. c. The total volume of supernatant with ethanol is processed through a single new Zymo-spin IIICG Column in step 7 (about 2.8 mL). This will require multiple spins to get the entire volume through the column. d. Proceed with the Zymo protocol as stated from step 8 on. e. Add an additional centrifuge spin (2 minutes, >12,000 x g) for step 17 is done to ensure the column is dry prior to the final elution step. This equates to two, two-minute spins for this step. This was added as we found that a single spin was insufficient to completely dry the column. f. Elute with 15µL of the supplied RNase-free, DNA-free water as stated in the protocol. g. Store the eluted RNA at -80 o C until analyzed. We recommend performing analysis as soon as possible on the RNA extracts to limit any degradation. RNA should be analyzed within one week of extraction and definitely not past three weeks.

1. The SARS-CoV-2 N1 and N2 RT-qPCRs along with the extraction control will be analyzed on the same 96-well PCR plate (three separate master mixes are required). All three RT-qPCRs are performed with the same thermocycling conditions. a. This RT-qPCR uses the iTaq Universal Probes One-step RT-qPCR reaction mix (BioRad Cat. 1725140). 2. Create a PCR log sheet report and update the mastermix tables for the appropriate number of samples to be analyzed (see Table 1 ) including the standard curves for N1, N2, and the AdV IPC extraction control RNA. a. Use in vitro transcribed (IVT) RNA standards for the N1 and N2 standard curves. IVT standards should be regenerated every three weeks. Currently, we are using the MAXIscript kit for IVT (Invitrogen cat. AM1320) with Turbo DNase (Ambion/Life technologies cat. AM1907) to eliminate the DNA template after transcription. 3. Wipe down the reagent preparation cabinet and the sample addition PCR cabinet along with any equipment that will be used with RNase displace (Fisher cat. 04-355-137) or equivalent before starting. Wash your gloves with RNase displace before beginning any work and as necessary thereafter. 4 . Take an aliquot of all three primer/probe sets (N1, N2, AdV IPC) out of the freezer and place into the reagent preparation PCR cabinet. Note that the N1 and N2 primer/probe sets come premixed from IDT at 6.7µM concentrations. The IPC primers and probe stock solutions are all 20 µM. SOP 1.1 3 5 . Place a tube of iTaq Universal Probes One-step RT-qPCR reaction mix and RT enzyme (BioRad cat. 1725140) into a 4 o C cooler rack. 6. Set up the RT-qPCR according to the specifications in the PCR log sheet and aliquot into a 96-well PCR plate. This is all done in the reagent preparation cabinet. 7. Take one pre-aliquoted tube of N1 and N2 in vitro transcribed RNA out of the -80 o C and place them in the sample preparation PCR cabinet. Dilute each RNA 10-fold out to the 10 -12 dilution (i.e. -12) with 50% glycerol/DEPC water. These will be used for the standard curves. 8. Take the samples out of the -80 o C freezer and place in a rack in the sample preparation PCR cabinet. 9 . Move the 96-well PCR plate with the mastermix to the sample preparation cabinet and add the appropriate amount of sample and/or standards to the designated wells (as outlined in the PCR log sheet, see Table 1 ). Seal the plate with PCR sealing foil, use a plate spinner to collect the volume in the bottom of each well. 10 . Perform the RT-qPCR on the LightCycler480 using the cycling conditions outlined in Table 2. 11. Analyze the data using the LightCycler480 software and ensure that the run meets the efficiency and detection limit QA criteria for the assay. a. Samples with a Cp greater than 40 cycles are considered negative. 12. Include the LC480 RT-qPCR data analysis report in the PCR log sheet report along with the analyst's write-up of the results. a. Calculate and report the concentrations in copies per milliliter of raw wastewater or copies per liter of raw wastewater. 

Sample processing/handling (or assay workflow) involves five steps:

2) Direct Viral Nucleic Acid Capture and Extraction

Also included in the workflow is determination of recovery by spiking MS2 phage in the sample and analysis % of MS2 phage recovered after the sample handling and processing.

Samples are pasteurized by heating at 60°C for 60 minutes in a water bath. 100ul of the sample before and after pasteurization is inoculated on an LB agar plate to examine the difference in bacterial viability. The pasteurized sample is held at 4°C and further processed within 48 hours or are frozen at -20°C for later processing and analysis. Frozen samples are thawed at 4°C prior to use.

Prior to sample concentration the 40 ml of pasteurized sample is spiked with41X10 5 PFU (plaque forming units) of MS2 phage. MS2 genetic material will copurify with the SARS-CoV-2 genetic material and indicate the % recovery of SARS-CoV-2.

• Take 40ml of pasteurized (or unpasteurized) in a 50 ml conical tube.

• To it add 12 ml of Binding Buffer 1 and 1 ml of Binding Buffer 2. Close the cap and mix well.

• Divide the mixture equally into two conical tubes containing 26 ml each. To each of the tubes add 24 ml of isopropanol. Mix well. • Assemble a column stack by nesting a PureYield™ Midi Clearing Column (blue) into the top of a PureYield™ Midi Binding Column (white). Place the assembled column stack onto the vacuum manifold as shown in Figure 1 .

Figure1. The blue clearing column inserted into the white binding column. The two columns sit on a vacuum manifold port.

• Pour the mixture onto the PureYield™ Midi Clearing Column Apply vacuum. The sample will pass through the clearing membrane in the PureYield™ Midi Clearing Column, and the Nucleic acid will bind to the binding membrane in the PureYield™ Binding Column. The PureYield™ Midi Clearing Column can hold 20 ml at a time, keep adding the sample at regular intervals and continue the vacuum until all the liquid has passed through both columns. • After all the sample has passed, switch off the vacuum to slowly release the vacuum from the filtration device before proceeding. Remove the PureYield™ Midi Clearing Column, leaving the PureYield™ Midi Binding Column on the vacuum manifold. This method allows for 40 ml of wastewater viral nucleic acid material to be simultaneously extracted and concentrated (1000x).

The qPCR assay for detection of SARS-CoV-2 genetic signal includes Three different primer/ probes set are designed, each as a 20X mixture detecting either the N1 or N2 fragment of the Nucleocapsid (N) gene or the Envelope protein (E) gene of SARS-CoV-2. The target SOP 1.2(H) genes are detected using Fluorescein dye-labelled probe. All the three 20X Primer/Probe mix also contain two additional controls: 1) a process control and 2) an internal amplification control.

The process control is designed to detect Pepper mild mottle virus (PMMoV), an abundant RNA virus found in wastewater samples. The primers and Quasar® 670 dye-labeled probe to amplify a 68bp region of PMMoV genome.

The 20X Primer/Probe /IAC Mix also contains primers, probe and template for an internal amplification control (IAC). The CAL Fluor® 560 dye-labeled probe detects the IAC, a novel DNA template that is included in every amplification reaction. The amplify a 435 bp product. Amplification performance of the IAC is used to detect PCR inhibitors (ex: Taq polymerase inhibitors) in the sample. This is the longest target in the SARS-CoV-2 RT-qPCR assay, making the IAC more sensitive to inhibitors than the other targets in the multiplex reaction.

The 20X Primer/Probe/IAC Mix also includes a reference dye (CXR) which has similar spectral properties as ROX.

GoTaq® WW Mastermix and the GoScript® Enzyme Mix, which are tolerant to a diverse range of PCR inhibitors, are used.

A Quantitation Standard SARS-CoV-2 dsDNA containing portions N and E genes, is used in the assay as a positive quantitation control. The stock concentration of this quantitative standard is at 2 x 10 6 copies/ ul. The quantitative standard was formulated internally at Promega Corporation b. The qPCR assay for detection of MS2 phage for spike recovery

For detection and quantification of MS2 phage RNA a separate 20X Primer/Probe/IAC mix is utilized. This mix includes primers and a FAM-dye-labeled probe for detection of MS2 genetic material. It also includes the process control primers and probe for detection of PMMoV and the primers, probe and template for the previously mentioned internal amplification control (IAC) and the reference dye CXR.

The MS2 phage genetic material is quantified using a linearized dsDNA standard. The dsDNA standard is at 2 x 10 6 copies/ul. An in-vitro transcribed RNA is also included as a positive control.

Note: To avoid contamination of samples with external sources of DNA and RNA template, perform all steps with filtered pipette tips.

i. Assemble qPCR Standard Curves using Quantitation Standard SARS-CoV-2 dsDNA. • Starting Quantitation Standard SARS-CoV-2 dsDNA:(2 x10^6 GU/μL) • Dilute Quantification Standard dsDNA 100-fold by mixing 2uL in 198uL nuclease-free water to obtain a concentration of 2 x 10^4 GU/uL • Perform subsequent serial 1:10 dilutions in low-bind 0.5 mL tubes: 5µL DNA + 45μL nuclease-free water to obtain the following standard curve tubes (2 x 10^3-2x10^0 copies/ul).

Copies/ well (5μL Sample Volume / reaction) RNA Equivalent: GU/ well (5μL Sample Volume / reaction) 10 20 ii. Assemble qPCR Standard curve for MS2 phage.

• Starting MS2 Quantification dsDNA concentration:(2 x10^6 GU/μL) • Dilute Quantification Standard dsDNA 100-fold by mixing 2uL in 198uL nuclease-free water to obtain a concentration of 2 x 10^4 GU/uL • Perform subsequent 1:10 dilutions in low-bind 0.5 mL tubes (e.g., Eppendorf

Cat. #:022431005), (5µL DNA + 45μL nuclease-free water) to obtain following standard curve tubes. Collect data from following fluorescence channels at end of 62°C Annealing/Extension step

• If no signal is obtained from the PMMoV reaction (Cy5-channel) , interpret as follows:

a. If the 2019-nCoV N1 or N2 or E are positive even in the absence of a positive PMMoV signal, the result should be considered valid. It is possible, that some samples may fail to exhibit PMMoV growth curves due to low viral (PMMoV) load. • If all 2019-nCoV markers, PMMoV (process control) and Internal Amplification control (IAC) are all negative for the specimen, the result should be considered invalid for the specimen. If residual specimen is available, repeat the extraction procedure and repeat the test. If all markers remain negative after re-test, report the results as invalid and a new specimen should be collected if possible. • Including both PMMoV and a dsDNA based Internal amplification control (IAC) helps dissect inhibition of two critical component of the RT-qPCR, reverse transcriptase and Taq polymerase.

The NTC consists of using nuclease-free water (Promega# P119) in the RT-qPCR reactions instead of RNA. The NTC reactions for all primer and probe sets should not exhibit fluorescence growth curves that cross the threshold line. If any of the NTC reactions exhibit a growth curve that crosses the cycle threshold before the lowest concentration standard on the standard curve, sample contamination may have occurred. Invalidate the run and repeat the assay with strict adherence to the guidelines. NTC samples will show amplification curves with only Internal Amplification Control (IAC) in the HEX channel.

Amplification from any other channel (FAM or Cy5) would indicate contamination of reagents/NTC reaction. 

Spike recovery is performed by spiking (seeding) approximately1x10 6 PFU MS2 phage to 40ml of the wastewater sample. The main assumption of the spike recovery analysis is that the MS2 count in the wastewater matrix is very low compared to the amount of virus used for spiking.

1mL of MS2 spiked wastewater input is purified using the PureYield Minicolumn as descrbed above (Fig. 4 ). This will be used to quantify the amount of virus seeded ( ) in copies/ml of influent. 5ul of total nucleic acid used in the RT-qPCR represents 125ul of wastewater influent.

40mL of wastewater is processed using the procedure mention above, resulting in a 40uL elution of purified viral nucleic acid. This will be used to quantify the recovered amount of virus ( ) in copies/ml of influent. 5ul of total nucleic acid used in the RT-qPCR represents 5 ml of wastewater influent.

% recovery ( r ) = ( ) x 100%

Quantitative Standard SARS-CoV-2 dsDNA containing portions of N and E genes at 2x 10 6 /ul will be titrated using serial log dilutions in a reference matrix (nuclease Free water) in a 5-log standard curve. The standard curve will be used to derive concentration of sample based on the Ct values.

Limit of detection (LOD) and Limit of quantification (LOQ) will be analyzed.

Promega has procedures to describe the process involved for equipment and calibrations using Promega's Electronic Resource Planning (ERP) system. The ERP system is used to inventory equipment, update equipment information, enter calibration information, complete calibrations, enter repair/pm information and generate reports. Calibration, repair, Metrology preventive maintenance and historical entries in the ERP will be made by the Metrology staff.

List of equipment used, and internal instrument ID Is listed: 

Analytical methods suitable for intended use will be performed as per Promega's QSOP14.006

The laboratory's Quality control checks for the SARS-CoV-2 assay includes:

In December 2019, an outbreak of a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) was detected in Wuhan, China. The outbreak quickly became a global pandemic , and by June 2020, over 10 million cases with over half a million deaths were reported. Early in the COVID- 19 pandemic, scientific studies demonstrated that the genetic material of SARS-CoV-2, an enveloped RNA virus, could frequently be detected in the feces of infected individuals and thereafter was also detected in wastewater. This finding mobilized the global water sector to investigate if wastewater-based epidemiology (WBE) using the genetic signal of SARS-CoV-2 could be used to track the spread of COVID-19 in communities. In the past, WBE was critical in identifying the community prevalence of poliovirus in support of the World Health Organization's (WHO) program to eradicate poliomyelitis. . Detection of SARS-CoV-2 in wastewater has the potential to provide an integrated, community-level indication of the presence or prevalence of COVID-19.

The process of detecting viral genetic signatures in wastewater samples involves collection of wastewater influent at specific points in the sewage system, either as a grab sample or as a 24-hour composite sample. This is followed by optional heat pasteurization and concentration of viral matter. The viral matter and/or its genetic signature is present at a low concentration in wastewater, making sample concentration a prerequisite for sensitive detection and utility in WBE. Concentration of viral matter can be performed using a variety of methods such as charged membrane filtration, centrifugal ultrafiltration and flocculation/precipitation using skimmed milk, or polyethylene glycol (PEG)/NaCl. Most of the viral concentration methods currently being used were originally developed to concentrate viral matter with the objective of culturing the virus for downstream applications, though they have been also used for direct PCR based detection. Several of the methods described above may work efficiently with several virus types, but they have proven to be inconsistent for SARS-CoV-2 RNA recovery leading to significant analytical variability. In addition, these viral concentration methods are labor intensive and time consuming.

To address these issues, we have developed a convenient method to capture and concentrate total nucleic acids (TNA) from a large volume of wastewater using silica based PureYield ® columns. The method uses a short protocol that minimizes the need for specialized laboratory equipment. In a first step total nucleic acid from a large volume sample (e.g. 40 ml of wastewater) is captured on a GFA/silica column (PureYield Midi Column). and then eluted in 1ml. In a second step the material is purified and concentrated using the PureYield Mini column. This method achieves consistent recovery rates and significant reduction in PCR inhibitors.

The total nucleic acid extracted using this kit may be analyzed for SARS-CoV-2 targets using the SARS-CoV-2 RT-qPCR kit for Wastewater (# CS317402, CS317409) or other methods If different sample volumes are tested the following scheme may be used: Using lower sample volume can reduce the sensitivity of your assay. SOP 1S.1(H) 7 . Remove the vacuum port cap and attach the PureYield™ Midi Column onto the vacuum manifold by pressing the nozzle gently into the vacuum port fitting as shown in Figure 2 . 13. Place the Eluator™ Device assembly onto a vacuum manifold ( Figure 3, Store sample at ≤ 20°C until further analysis. TNA purified using this method can be directly used for RT-qPCR. This rapid and economical method employs common laboratory reagents to extract and directly capture RNA from wastewater using salt-based lysis and silica mediated nucleic acid capture to recover high quality wastewater RNA.

Sample volumes as low as 40 mL have proven sufficient to detect low-abundance viruses such as SARS-CoV-2 present in Bay Area wastewater. This method can be used to detect SARS-CoV-2 RNA in wastewater volumes ranging from 40 mL to 1 L. Further, the method enriches all wastewater RNAs without bias, enabling the simultaneous purification and detection of viral RNAs of interest alongside wastewater human fecal load markers suitable for "fecal load" normalization. Below is a protocol of the steps needed to extract RNA from 40mL of wastewater. Refer to EPA Method 1602 for the list of required equipment, supplies, and reagents for the matrix spike assays.

In this addendum, dashed lines (------) are used to highlight sections with large additions and/or sections that are highly modified.

Addendum to EPA Method 1615:

1.1 Method has been modified to also include culture and/or molecular procedures for adenovirus, SARS-CoV-2, betacoronavirus OC43 (matrix spike), MS2 (matrix spike); and PhiX174 (matrix spike). The method has been modified specifically for use with raw wastewater. 2.0 Significant modifications have been made. 6.1

Not applicable. The sample will not be filtered. 6.2 Not applicable -WWTP will do the sample collection. 6.3.1

Not applicable. Matrix spike sample is same as field sample. 6.3. 6 Not applicable. The sample will not be filtered. 6.3.7

Not applicable. Matrix spike sample is same as field sample. 6.3.8

Not applicable. The sample will not be filtered. 6.4

Not applicable. The sample will not be processed by the filtration/elution/organic flocculation method in 1615. 10.0 & 11.0 Concentration and Purification has been modified for analysis of raw wastewater. 12.0

Addition of Adenovirus and SARS-CoV-2/betacoronavirus OC43 analysis 13.0

Modification from two-step RT-qPCR procedure to a one-step RT-qPCR procedure. Some primer sets have been modified or added. When all cells have been lifted from the flask surface, spray around the cap of the flask with 70% ethanol solution and place in the BSC. Using an appropriate size pipette, aseptically add pre-warmed growth media (equivalent to the amount of trypsin in the flask) and rinse bottom of flask with cell suspension several times. 10.

If enumeration is necessary, transfer the entire content to a sterile tube and tightly cap the tube. Concentrate the cells by centrifugation (400 x g, 2 min or 175 x g, 6 min) and discard supernatant. Re-suspend cells in 10 mL of pre-warmed growth media. Be sure to break up clumps by vigorously pipetting suspension up and down in tube.

Allow the suspension to settle for 1 min and remove a 50 µL aliquot with a sterile pipette tip and place in 1.5 mL Eppendorf tube containing 50 µL Trypan Blue. Flick tube to mix and perform a hemocytometer count to determine the concentration of viable cells.

Transfer an appropriate amount of cells to the culture flask containing pre-warmed growth media Flask Size Seeding Density Days until Confluent 75 0.75 x 10 6 3-4 225 1 x 10 6 4-7 6-well plate 1 x 10 6 (~3 x 10 5 per well) 1-2

Place flask in incubator at 37.0 ± 1°C under 5% CO2. Place well plates into a Ziploc™ bag before placing into incubator. 14.

If cells are not confluent within the expected time frame, replace media. Aseptically remove old media using a sterile pipette. Replace with pre-warmed maintenance media. Place flask back in incubator until cells are confluent. SOP 2.1 Aseptically add pre-warmed PBSA to flask. Do not put the pipet down or touch the tip to anything. Gently tilt flask to rinse residual growth medium from cells. Using the same pipette or a new pipette, remove the PBSA from flask without disturbing cells and discard in waste beaker. Repeat once more. This removes any media that contains serum, a trypsin inhibitor. If the pipette is put down or the tip touches any object use a new sterile pipette to remove PBS rinse from culture flask. When all cells have been lifted from the flask surface, spray around the cap of the flask with 70% ethanol solution and place in the BSC. Using an appropriate size pipette, aseptically add pre-warmed growth media (equivalent to the amount of trypsin in the flask) and rinse bottom of flask with cell suspension several times. 10.

If enumeration is necessary, transfer the entire content to a sterile tube and tightly cap the tube. Concentrate the cells by centrifugation (400 x g, 2 min or 175 x g, 6 min) and discard supernatant. Re-suspend cells in 10 mL of pre-warmed growth media. Be sure to break up clumps by vigorously pipetting suspension up and down in tube.

Allow the suspension to settle for 1 min and remove a 50 µL aliquot with a sterile pipette tip and place in 1. 

Place flask in incubator at 37.0 ± 1°C under 5% CO2. Place well plates into a Ziploc™ bag before placing into incubator. 14.

If cells are not confluent within the expected time frame, replace media. Aseptically remove old media using a sterile pipette. Replace with pre-warmed maintenance media. Place flask back in incubator until cells are confluent. 15.

If cells used for bioassay are not 80-90% confluent within 1-3 days the flasks should be discarded. An older monolayer will not optimally support an infection. 16 .

Autoclave media waste and any media that have had contact with cells or serum before discarding. 17.

Discard cells after they have been passaged a total of 200 times.

OC43 Primers/Probe for Molecular Assay. 

The QA/QC requirements for this project are summarized in the following Enveloped Viruses: Process and analyze the positive QC sample by adding 1ml of 10 6 GCMPN/ml OC43 virus to 1100 ml of laboratory deionized water and process (see the modified concentration/purification procedure; Sections 10 and 11, below), OC43 molecular assay.

Laboratory performance for the positive QC samples conducted for this study will be compared to the acceptance criteria in Appendix D of RFQ 4952 8.5

PT and PE samples not required. Once contracted, the labs will perform the precampaign testing that will include some demonstration of capability testing. The scope of this testing is described in RFQ 4952. 8.6.1

Enteric viruses: Run a matrix spike for every other field sample from each site (during the pre-campaign testing, a matrix spike will be run with every field sample). 8.6.1.1

Enveloped viruses: Run a matrix spike for every field sample from each site.

Replace with the following steps:

6.2 REPLACEMENT: To the samples that will include a matrix spike, complete the following steps:

1. Spike 10 8 PFU of MS2 to 1100 mL of the field sample (the same sample that is used for measuring the native virus). This number can be achieved by adding approximately 0.1 mL of a MS2 spiking suspension with a concentration of approximately 10 9 PFU/mL (may adjust the volume of the MS2 spiking suspension added based on the actual concentration of the spiking suspension to achieve a minimum concentration of MS2 in the field sample of 10 8 PFU/L).

To this same sample, spike 10 8 PFU of PhiX174. This number can be achieved by adding approximately 0.1 mL of a PhiX174 spiking suspension with a concentration of approximately 10 9 PFU/mL (may adjust the volume of the PhiX174 spiking suspension added based on the actual concentration of the spiking suspension to achieve a minimum concentration of PhiX174 in the field sample of 10 8 PFU/L). 3. Spike 10 7 GCMPN/ml of OC43 to 1100 ml of the field sample (the same sample that has been spiked with MS2 and PhiX174 and is used for measuring the native virus). This number can be achieved by adding approximately 1ml of an OC43 spiking suspension with a concentration of approximately 10 7 GCMPN/ml (may adjust the volume of the OC43 spiking suspension added based on the actual concentration of the spiking suspension to achieve a minimum concentration of OC43 in the field sample of 10 7 GCMPN/L).

Process and analyze the sample using the sample procedures that are used for the samples without the matrix spike with the exception that this sample will also For enveloped viruses, report the concentration as determined from rt-qPCR standard curve.

Laboratory performance for the MS samples conducted for this study will be compared to the acceptance criteria in Appendix D of RFQ 4952.

Replace this step with the following: A 4 L raw wastewater sample will be collected by the wastewater treatment facility staff and will be delivered to the lab. The sample should be labeled with a unique sample number. The facility staff should record the unique sample number, facility name, sampler's name, location at sampling site, date, and time on a sample data sheet 9.2.

Procedure is same only the 4 L sample will not be filtered so there is no cartridge housing or intake/discharge module. The sample should be shipped cold (1-10 C) not frozen. 9.3.2

Labs will receive a 4 L sample (using a portion for measuring virus, a portion for protozoa, and a portion for phage). The samples will not be filtered, so the lab will not receive a cartridge filter.

Skip these steps. Instead complete the following modified concentration/purification procedure: b. Centrifuge the filter at 4000-5000 x g for 30 minutes or until the concentrate is reduced to less than 1 mL. c. Record initial and final volume. Resuspend concentrate and transfer to sterile 1.5 mL sterile tube. Store at 4 +/-3 C for up to 24 hours or at -80 C until extraction. Proceed to SECTION 13 (Molecular Analysis).

Slowly adjust pH of the remaining sample (approximately 1 L) for enteric virus analysis to 9.5 +/-0.1 using 1-3 N NaOH. Stir at room temperature for an additional 60 minutes, confirm pH is still in range after 30 minutes. 6.

Transfer into 250-or 500-mL centrifuge tubes. Centrifuge at 3,000 x g for 20 minutes (brake no more than 20%). 7.

Decant or pipet supernatant into 1 L container and record the volume. Discard pellets. 8.

Check pH of supernatant using pH meter and adjust to 7.2+/-0.2 using 1-3 N HCL. 9.

Add 52 g of Sodium chloride (NaCl) and mix/stir to dissolve then add 120 g PEG 8000and Mix by inversion or stirring for minimum 2 hours/ or up to 20 hours at 4 +/-3 C 10.

If necessary, transfer to appropriate centrifuge tube. Centrifuge at a minimum of 4,000 x g for 45 mins at 4 C (Brake at no more than 20%).

Carefully decant and discard the supernatant. Invert tube over a paper towel for up to 30 seconds to ensure liquid removal from tube. 12.

Resuspend the pellet in 1-2 mL of cold PBS. Mix with pipet tip. Avoid making bubbles. Do not vortex.

Quantitatively Transfer (using additional 0.5 mL cold PBS) the re-dissolved pellet to a 15 mL chemical resistant centrifuge tube 14.

Record the re-dissolved pellet final volume resulting from the previous step (designated Final Concentrated Sample Volume, FCSV) on the virus data sheet. 15. Add 4 mL (or twice the volume of the transferred volume if it is greater than 2.5 mL) of chloroform/butanol solution. Vortex and let stand for 5 minutes. 16 .

Centrifuge at minimum of 13500 x g for 15 minutes at 4 C 17.

Using a micropipette, transfer the top layer (the aqueous phase) to a sterile 15mL centrifuge tube (approximately 2 mL). Chloroform will be on the bottom. Avoid transferring chloroform, go slowly and do not slant tube while transferring.

Record the weight of the 15 mL centrifuge tube before and after transfer. Record both and calculate saved volume. Record this volume (designated FCSV recovered after extraction) on the virus data sheet. 19 .

The pellet/concentrate can be held for up to 18 hours in refrigerator or frozen at -80 C for longer storage. Freezing and thawing can lead to virus losses so avoid multiple freeze/thaw cycles. 20.

A portion of the pellet/concentrate will proceed to nucleic acid extraction, a portion of the pellet/concentrate will be diluted and then proceed to the culture assays, and the remaining portion of the pellet/concentrate will be frozen for backup/archival purposes. a. 0.4 mL of the pellet shall be diluted to a total volume of 4 mL using cold PBS. i. 1.35 mL of the 4 mL re-dissolved pellet/concentrate will be used for the enterovirus culture assay (called subsample 1) ii. 1.35 mL of the 4 mL re-dissolved pellet/concentrate will be used for the adenovirus culture assay (called subsample 1B) iii. 0.3 mL of the 4 mL re-dissolved pellet/concentrate will be used for the MS2 and PhiX174 culture assay (called subsample 1C) iv. The rest of the 4 mL re-dissolved pellet/concentrate will be frozen at -70 C for backup and archival purposes b. 1 mL of the pellet will be used for nucleic acid extraction (called subsample 2) c. The remaining pellet will use frozen at -70 C for backup and archival purposes (called subsample 3) 

The inoculum volume is 0.1 mL. Record the Inoculum Volume on the virus data sheet. The number of cell culture replicates should be 10.

The laboratories should prepare 10-and 100-fold dilutions for every analysis of the raw wastewater samples. 12.1.2.3.1

The 10-fold dilution is prepared by diluting 0.3 mL of subsample 1 (from step 17.a.i; Section 10 and 11, above) to a volume of 3.0 mL with cold PBS. 12.1.2.3.2

The 100-fold dilution is prepared by diluting 0.3 mL of the 10-fold dilution to a volume of 3.0 mL with cold PBS 12.1.2.4

The lab must perform these negative controls 12.1.2.5

The lab must perform these positive controls 12. 

Four dilutions of concentrate will be analyzed in duplicate for each coliphage type. As a result, nine double-agar layer plates will be required for each coliphage type: two plates per dilution (0.1, 0.01, 0.001, 0.0001) and one method blank plate.

Dilutions: a. Four dilutions will be needed: 0.1, 0.01, 0.001, 0.0001. Note: Subsample 1C (prepared in step 17.a.iii of the modified concentration/purification procedure; section 10 and 11, above) is already 0.1 dilution. Additional dilutions (beyond 0.0001) may be necessary. PBS (or PBW) is used as the diluent and is used to prepare the negative control. b. To prepare the dilutions, aseptically add 0.9 mL of PBS (or PBW) into each of four (or more) sterile dilution tubes. Label them as "0.01," "0.001," "0.0001," "method blank," etc. c. Add 0.1 mL of the subsample 1C (from step 17.a.iii of the modified concentration/purification procedure; section 10 and 11, above) to the tube of PBS (or PBW) labeled "0.01." d. Cap the tube and vortex for 5 seconds on a medium-high setting (if available) or until well-mixed. e. Add 0.1 mL of the well-mixed 0.01 dilution to a tube with 0.9 mL of PBS (or PBW) labeled "0.001". f. Cap the tube and vortex for 5 seconds on a medium-high setting (if available) or until well-mixed. g. Add 0.1 mL of the well-mixed 0.001 dilution to a tube with 0.9 mL of PBS (or PBW) labeled "0.0001." Cap the tube and vortex for 5 seconds on a medium-high setting (if available) or until well-mixed. h. Add 0.1 mL of PBS (or PBW) the tube labeled "method blank." Cap the tube and vortex for 5 seconds on a medium-high setting (if available) or until well-mixed.

Agar preparation: a. Place TSA molten agar with respective antibiotics in a 48-53 C water bath. The agar should remain molten in the water bath until ready for use. 18 Preparation of plates for enumeration of somatic coliphage: a. With the agar still in the water bath, aseptically inoculate tube containing nalidixic acid with 100 L of log-phase E. coli CN-13. b. Immediately add 100 L (0.1 mL) of subsample 1c (from step 17.a.iii of the modified concentration/purification procedure; section 10 and 11, above). c. Add 12-15 mL molten agar d. Mix the inoculum by rolling the tube briefly in palm of hand. e. Pour contents into one of the two petri plates marked "undiluted, E. coli  somatic." f. Duplicate analysis-Repeat Sections 5a through 5d for the duplicate. g. Repeat Sections 5a through 5e for each dilution volume.

Preparation of plates for enumeration of male-specific (F + ) coliphage-Repeat Section 5 using agar containing ampicillin/streptomycin and log-phase E. coli F amp 7.

Preparation of somatic coliphage method blank: a. With the agar still in the water bath, aseptically inoculate a tube containing nalidixic acid with 100 L of log-phase E. coli CN-13. b. Immediately add 100 L (0.1 mL) of TSB from the "method blank" dilution tube.

Add 12-15 mL molten agar. Mix the inoculum by rolling the tube briefly in palm of hand. c. Pour contents into a petri plate marked "method blank, E. coli CN-13, somatic."

Preparation of the male-specific (F + ) coliphage method blank-Repeat Section 7 using agar containing ampicillin/streptomycin and log-phase E. coli F amp . 9.

After the agar hardens, invert the plates and incubate for 16 to 24 hours at 36 C ± 1.0 C. 10.

Circular zones of clearing (typically 1 to 10 mm in diameter) in lawn of host bacteria after 14 to 24 hours of incubation are plaques. Count the number of 

Follow manufacturer instructions in commercial kit (Zymo Quick-DNA/RNA Viral Kit # D7020) or equivalent.

Add 2 parts of Viral DNA/RNA Buffer to 1 part of sample and mix well (DNA/RNA Shield step is not necessary).

Transfer 700 μl of the mixture into one IIC-XL Column in a collection tube and centrifuge @ 10,000 x g for 1-2 minutes. Transfer the column into a new collection tube.

Reload the column with another 700 μl of the mixture and repeat centrifuge. Repeat until all of the mixture has been passed through the column.

Add 500 μl Viral Wash Buffer to the column, centrifuge for 30 seconds @ 10,000 x g and discard the flow-through. Repeat this step.

Add 500 μl ethanol (95-100%) to the column and centrifuge for 1 minute @ 10,000 x g to ensure complete removal of the wash buffer. Carefully, transfer the column into a 1.5 mL nuclease-free tube. 7.

Add DNase/RNase-Free Water directly to the column matrix and centrifuge for 30 seconds @ 10,000 x g. 8.

The final extraction concentrate volume is 0.2 mL (enteric viruses) and 0.05 mL (0.1 mL in total) (coronaviruses) 9.

Refrigerate at 4 C for a maximum of 24 hours or <-20 C for up to one week until PCR analysis. Indefinite storage @ -80 C. 10.

Extract RNA from poliovirus, MS2, PHIX174, and OC43 stocks following the protocol above to calculate percent recoveries. These two steps may be completed as a one-step reaction (i.e., reverse transcription should be completed in the same tube as qPCR); Each assay will be completed in triplicate. • For RT-qPCR 1-step assays: Refer run conditions for each primers/probe is specified in Tables 5 though 11 • For qPCR assays: refer to run conditions specified in Tables 10, and 12 • SARS-CoV-2 CDC N gene RT-qPCR (One step) assays: Run condition is specified in Table 14 • WHO E gene RT-qPCR (One step) assay: Run condition is specified in Table  15 Confirm (move if necessary) the threshold line lies within the exponential phase of the fluorescence curves and above any background signal.

Use the following equation to calculate genome copies per liter in the original sample rather than Eq. 5 in EPA 1615:

GCoriginal sample per L = Calculate genome copies per liter in the original sample GCassay = Genome copies measured from the qPCR assay Vnucleic acid extract = Volume of the concentrate after nucleic acid extraction (should be 0.2 mL) FCSV = Final concentrated sample volume (before chloroform extraction) (should be 2.0 mL) DF = dilution factor = the reciprocal of any dilution performed to compensate for inhibition (e.g., 10 and 100 for the 1:10 and 1:100 dilutions) Vassay = volume of the nucleic acid extraction used for each (rt)qPCR assay (should be 0.006 mL) Vpellet for molecular = volume of the re-dissolved pellet/concentration used for nucleic acid extraction (should be 1 mL) TSV = total sample volume (should be 1 L) 13.5.7 skip 13.6

The laboratory must use hepatitis G armored RNA as an inhibition control in all assays. The laboratory may option 1, 2, or 3 of 1615 as long as the inhibition control is run for all assays. 13.7

Armored RNA containing the enterovirus, norovirus GI, and norovirus GII sequences, (Armored RNA 1615 from Asuragen) will be used for preparing the standard curves. For OC43 assay, standard Curve is prepared from OC43 virus serially diluted from 10 6 GCMPN /5 uL to 10 However, due to variability in stock Armored RNA Gene copies ( up to ±20%), it is highly recommended to determine the GC-MPN/ml titer of the stock armored RNA using the following steps; 13.7.1 Prepare 10-fold serial dilution (in TSM buffer) 13.7.2

Use the highest three dilutions (10, 100,1000) and 10 replicates per dilution. 13.7.3

Perform RT-qPCR and qPCR (section 13.5) using primers and probe. 13.7.4 Obtain GC-MPN/ml for Armored RNA using EPA most probable Number Calculator or equivalent. Change the calculator's "Number of Dilutions" to 3, the "Number of Tubes per dilution" to 10, and the "Dilution Type" to Standard 10-Fold Serial. For each stock, input the number of positive replicates from the highest dilution giving at least one positive replicate and from the next two lower dilutions.

For this project, a full standard curve will be required for every sample. It is not acceptable to use stored standard curves and calibrators. 14.0

While the information in this section provides good perspective, the acceptance criteria given in Appendix D of the RFQ will be used for this study instead of the acceptance criteria in EPA 1615 (for both matrix spikes and positive QC samples). 16 , Table 2 Not applicable Table 4 For 1-step: set up the thermocycler program and run with a setting of 1 cycle hold at 50 °C for 10 min, 1 cycle hold at 95 °C for 2 min, followed by 40 cycles of 95 °C for 10 sec, and 60 °C for 60 sec (capture fluorescence). Use Option 1 if standards are prepared to correspond to 6 ul per reaction-Use Option 2 if standards are prepared to correspond to 5 ul per reaction volume. For 1-step: set up the thermocycler program and run with a setting of 1 cycle hold at 50 °C for 10 min, 1 cycle hold at 95 °C for 2 min, followed by 40 cycles of 95 °C for 10 sec, and 60 °C for 60 sec (capture fluorescence). Use Option 1 if standards are prepared to correspond to 6 ul per reaction-Use Option 2 if standards are prepared to correspond to 5 ul per reaction volume. PhiX174 Thermal cycler qPCR program: 5 min at 94°C and then 40 amplification cycles including denaturation at 94°C for 15 s and annealing and elongation at 60°C for 60 s, followed by fluorescence measurement. Or 95°C for 2 min, followed by 40 cycles with a 95°C denaturation for 10 s, 55°C annealing for 30 s, and 72°C elongation for 15 s (Adenovirus assay conditions) -Use Option 1 if standards are prepared to correspond to 6 ul per reaction-Use Option 2 if standards are prepared to correspond to 5 ul per reaction volume. Adenovirus Thermal cycler qPCR: Hot-start denaturation step at 95°C for 2 min, followed by 40 cycles with a 95°C denaturation for 10 s, 55°C annealing for 30 s, and 72°C elongation for 15 s -Use Option 1 if standards are prepared to correspond to 6 ul per reaction-Use Option 2 if standards are prepared to correspond to 5 ul per reaction volume. 

EPA Method 1615 along with the following addendum shall be used to process and analyze the virus sample by both culture and molecular methods. Many modifications have been made to EPA Method 1615, including revisions to the concentration/purification steps, addition of a culture and molecular procedure for adenovirus; a molecular procedure for SARS-CoV-2 and betacoronavirus OC43 (enveloped viruses); and revisions to the matrix spike organism, method, and frequency. The addendum lists the method modifications and clarifies certain steps in EPA Method 1615. Follow all of the steps in EPA Method 1615 unless otherwise specified by the addendum.

Refer to EPA Method 1602 for the list of required equipment, supplies, and reagents for the matrix spike assays.

In this addendum, dashed lines (------) are used to highlight sections with large additions and/or sections that are highly modified.

Addendum to EPA Method 1615:

1.1 Method has been modified to also include culture and/or molecular procedures for adenovirus, SARS-CoV-2, betacoronavirus OC43 (matrix spike), MS2 (matrix spike); and PhiX174 (matrix spike). The method has been modified specifically for use with raw wastewater. 2.0 Significant modifications have been made. 6.1

Not applicable. The sample will not be filtered. 6.2 Not applicable -WWTP will do the sample collection. 6.3.1

Not applicable. Matrix spike sample is same as field sample. 6.3. 6 Not applicable. The sample will not be filtered. 6.3.7

Not applicable. Matrix spike sample is same as field sample. 6.3.8

Not applicable. The sample will not be filtered. 6.4

Not applicable. The sample will not be processed by the filtration/elution/organic flocculation method in 1615. 10.0 & 11.0 Concentration and Purification has been modified for analysis of raw wastewater. 12.0

Addition of Adenovirus and SARS-CoV-2/betacoronavirus OC43 analysis 13.0

Modification from two-step RT-qPCR procedure to a one-step RT-qPCR procedure. Some primer sets have been modified or added. 

Not applicable. Matrix spike will be MS2 and PhiX174 for the enteric viruses ,rather than Sabin Poliovirus 3, and OC43 for enveloped viruses,. 7. 3 Not applicable. The sample will not be processed by the filtration/elution/organic flocculation method in 1615

In addition to the reagents, media, and standards specified in 1615, the following reagents and standards will be needed:

1.

Purity of Reagents: ACS reagent grade chemicals shall be used in all tests. Unless otherwise indicated, reagents shall conform to the specifications of the Committee on Analytical Reagents of the American Chemical Society. The microbiological growth media must be of microbiological grade.

Chloroform:Butanol: Add equal parts chloroform and butanol together. Shake to mix. Store for three months refrigerated. Note: do not use chloroform:butanol reagent with the enveloped virus procedure.

Phosphate Buffered Saline (PBS): Add 8g NaCl, 0. and Leibovitz L-15 medium with L-glutamine (Sigma-Aldrich, Cat. No. L4386), 1 mL/L of 7.5% sodium bicarbonate, 10 mL/L of antibioticantimycotic solution, and 20 mL/L of fetal bovine serum and may be used for incubation of inoculated flasks at 37 ± 1.0°C without CO2.

A549 cell culture.

Warm all reagents to 37°C prior to use in this procedure.

Growth media and maintenance media are as described for BGM cells, briefly: a. Growth Medium (10% FBS in DMEM): To each 1L sterile bottle of DMEM add 115 mL FBS, 11.52 ml Antibiotic, 11.5mL Antimycotic, and 11.5 mL Kanamycin or Gentamycin. b. Maintenance Medium consists of 2% FBS in DMEM or a 50/50 mixture of DMEM and Leibovitz L-15 medium with L-glutamine (Sigma-Aldrich, Cat. No. L4386), 1 mL/L of 7.5% sodium bicarbonate, 10 mL/L of antibiotic-antimycotic solution, and 20 mL/L of fetal bovine serum and may be used for incubation of inoculated flasks at 37 ± 1.0°C without CO2.

Turn on UV light and blower in biosafety cabinet (BSC) for a minimum of ½ hr before working in hood. Be sure that tube racks that will be used are placed in the BSC while the UV light is on. Immediately prior to working in hood switch the UV light off. If the UV light is left on, exposed skin will burn. Remove the cells to be split from the incubator and spray the cap and neck of the flask with 70% ethanol before placing the flask in the BSC. Place pre-wrapped sterile pipettes in the BSC. Remove the PBSA and the trypsin-EDTA solution from 37°C and spray the outside and cap of each vial with 70% ethanol. Place the tubes in a rack in the BSC and loosen caps.

Remove the spent growth medium from the culture flask. Tilt the flask away from the cell monolayer to avoid disturbing it. Place spent media in waste beaker located in the BSC. 6.

Aseptically add pre-warmed PBSA to flask. Do not put the pipet down or touch the tip to anything. Gently tilt flask to rinse residual growth medium from cells. Using the same pipette or a new pipette, remove the PBSA from flask without disturbing cells and discard in waste beaker. Repeat once more. This removes any media that contains serum, a trypsin inhibitor. If the pipette is put down or the tip touches any object use a new sterile pipette to remove PBS rinse from culture flask. Remove growth media from 37°C and spray with 70% ethanol solution and place in BSC. Be sure to loosen the cap. 9.

When all cells have been lifted from the flask surface, spray around the cap of the flask with 70% ethanol solution and place in the BSC. Using an appropriate size pipette, aseptically add pre-warmed growth media (equivalent to the amount of trypsin in the flask) and rinse bottom of flask with cell suspension several times. 10.

If enumeration is necessary, transfer the entire content to a sterile tube and tightly cap the tube. Concentrate the cells by centrifugation (400 x g, 2 min or 175 x g, 6 min) and discard supernatant. Re-suspend cells in 10 mL of pre-warmed growth media. Be sure to break up clumps by vigorously pipetting suspension up and down in tube.

Allow the suspension to settle for 1 min and remove a 50 µL aliquot with a sterile pipette tip and place in 1.5 mL Eppendorf tube containing 50 µL Trypan Blue. Flick tube to mix and perform a hemocytometer count to determine the concentration of viable cells.

Transfer an appropriate amount of cells to the culture flask containing pre-warmed growth media Flask Size Seeding Density Days until Confluent 75 0.75 x 10 6 3-4 225 1 x 10 6 4-7 6-well plate 1 x 10 6 (~3 x 10 5 per well) 1-2

Place flask in incubator at 37.0 ± 1°C under 5% CO2. Place well plates into a Ziploc™ bag before placing into incubator. 14.

If cells are not confluent within the expected time frame, replace media. Aseptically remove old media using a sterile pipette. Replace with pre-warmed maintenance media. Place flask back in incubator until cells are confluent.

If cells used for bioassay are not confluent within 1-4 days the flasks should be discarded. An older monolayer will not optimally support an infection. 16 .

Autoclave media waste and any media that have had contact with cells or serum before discarding. 17.

Discard cells after they have been passaged a total of 200 times. 

QuantaBio qScript™ XLT One-Step RT-qPCR ToughMix® or equivalent 3.

ABI real-time PCR Machine (or equivalent) 4. strip tubes and caps or 96 well plates and optical film 5.

Standards for preparing the standard curve. For checking of sterility, aseptically transfer 5 mL of the growth medium to a sterile tube and incubate in the CO2 incubator at 37 ± 1.0°C for a minimum of 2-3 days. Look for contamination (turbidity) and discard if contamination is evident. Store media at 4°C for up to 6 months or earliest expiration date of reagents. ii. Optionally, maintenance medium consists of a 50/50 mixture of DMEM and Leibovitz L-15 medium with L-glutamine (Sigma-Aldrich, Cat. No. L4386), 1 mL/L of 7.5% sodium bicarbonate, 10 mL/L of antibioticantimycotic solution, and 20 mL/L of fetal bovine serum and may be used for incubation of inoculated flasks at 37 ± 1.0°C without CO2.

HRT cell culture (HRT-18G (ATCC CRL-11663)).

Warm all reagents to 37°C prior to use in this procedure.

Growth media and maintenance media are as described for BGM cells, briefly: i. Growth Medium (10% FBS in DMEM): To each 1L sterile bottle of DMEM add 115 mL FBS, 11.52 ml Antibiotic, 11.5mL Antimycotic, and 11.5 mL Kanamycin or Gentamycin. ii. Maintenance Medium consists of 2% FBS in DMEM or a 50/50 mixture of DMEM and Leibovitz L-15 medium with L-glutamine (Sigma-Aldrich, Cat. No. L4386), 1 mL/L of 7.5% sodium bicarbonate, 10 mL/L of antibioticantimycotic solution, and 20 mL/L of fetal bovine serum and may be used for incubation of inoculated flasks at 37 ± 1.0°C without CO2.

Turn on UV light and blower in biosafety cabinet (BSC) for a minimum of ½ hr before working in hood. Be sure that tube racks that will be used are placed in the BSC while the UV light is on. Immediately prior to working in hood switch the UV light off. If the UV light is left on, exposed skin will burn. Remove the cells to be split from the incubator and spray the cap and neck of the flask with 70% ethanol before placing the flask in the BSC. Place pre-wrapped sterile pipettes in the BSC. Remove the PBSA and the trypsin-EDTA solution from 37°C and spray the outside and cap of each vial with 70% ethanol. Place the tubes in a rack in the BSC and loosen caps.

Remove the spent growth medium from the culture flask. Tilt the flask away from the cell monolayer to avoid disturbing it. Place spent media in waste beaker located in the BSC.

Aseptically add pre-warmed PBSA to flask. Do not put the pipet down or touch the tip to anything. Gently tilt flask to rinse residual growth medium from cells. Using the same pipette or a new pipette, remove the PBSA from flask without disturbing cells and discard in waste beaker. Repeat once more. This removes any media that contains serum, a trypsin inhibitor. If the pipette is put down or the tip touches any object use a new sterile pipette to remove PBS rinse from culture flask. Remove growth media from 37°C and spray with 70% ethanol solution and place in BSC. Be sure to loosen the cap. 9.

When all cells have been lifted from the flask surface, spray around the cap of the flask with 70% ethanol solution and place in the BSC. Using an appropriate size pipette, aseptically add pre-warmed growth media (equivalent to the amount of trypsin in the flask) and rinse bottom of flask with cell suspension several times. 10.

If enumeration is necessary, transfer the entire content to a sterile tube and tightly cap the tube. Concentrate the cells by centrifugation (400 x g, 2 min or 175 x g, 6 min) and discard supernatant. Re-suspend cells in 10 mL of pre-warmed growth media. Be sure to break up clumps by vigorously pipetting suspension up and down in tube.

Allow the suspension to settle for 1 min and remove a 50 µL aliquot with a sterile pipette tip and place in 1.5 mL Eppendorf tube containing 50 µL Trypan Blue. Flick tube to mix and perform a hemocytometer count to determine the concentration of viable cells. 12.

Transfer an appropriate amount of cells to the culture flask containing pre-warmed growth media Flask Size Seeding Density Days until Confluent 75 0.75 x 10 6 3-4 225 1 x 10 6 4-7 6-well plate 1 x 10 6 (~3 x 10 5 per well)

Place flask in incubator at 37.0 ± 1°C under 5% CO2. Place well plates into a Ziploc™ bag before placing into incubator. 14.

If cells are not confluent within the expected time frame, replace media. Aseptically remove old media using a sterile pipette. Replace with pre-warmed maintenance media. Place flask back in incubator until cells are confluent. 15.

If cells used for bioassay are not 80-90% confluent within 1-3 days the flasks should be discarded. An older monolayer will not optimally support an infection. 16 .

Autoclave media waste and any media that have had contact with cells or serum before discarding. 17.

Discard cells after they have been passaged a total of 200 times.

OC43 Primers/Probe for Molecular Assay.

1.

OC43 (Integrated DNA Technologies or equivalent):

1.

Coronavirus SARS-CoV -Primers/Probe (2019-nCoV CDC EUA Kit, 500 rxn Cat# 1000660 from Integrated DNA Technologies or equivalent) 2.

Zymo Quick-DNA/RNA Viral Kit # D7020) or equivalent.

QuantaBio qScript™ XLT One-Step RT-qPCR ToughMix® or equivalent 4.

ABI real-time PCR Machine (or equivalent) 5.

strip tubes and caps/ 96 well plates and optical film 6.

Standard for preparing the standard curve: Plasmid linearized by Cel serially diluted

The QA/QC requirements for this project are summarized in the following Enteric Viruses: Process and analyze the positive QC sample using the PEG flocculation/chloroform extraction procedure (see the modified concentration/purification procedure; Sections 10 and 11, below), enterovirus culture assay, and enterovirus molecular assay. 8.4.2.7

Enveloped Viruses: Process and analyze the positive QC sample by adding 1ml of 10 6 GCMPN/ml OC43 virus to 1100 ml of laboratory deionized water and process (see the modified concentration/purification procedure; Sections 10 and 11, below), OC43 molecular assay.

Laboratory performance for the positive QC samples conducted for this study will be compared to the acceptance criteria in Appendix D of RFQ 4952 8.5

PT and PE samples not required. Once contracted, the labs will perform the precampaign testing that will include some demonstration of capability testing. The scope of this testing is described in RFQ 4952. 8.6.1

Enteric viruses: Run a matrix spike for every other field sample from each site (during the pre-campaign testing, a matrix spike will be run with every field sample). 8.6.1.1

Enveloped viruses: Run a matrix spike for every field sample from each site.

Replace with the following steps:

To the samples that will include a matrix spike, complete the following steps:

1. Spike 10 8 PFU of MS2 to 1100 mL of the field sample (the same sample that is used for measuring the native virus). This number can be achieved by adding approximately 0.1 mL of a MS2 spiking suspension with a concentration of approximately 10 9 PFU/mL (may adjust the volume of the MS2 spiking suspension added based on the actual concentration of the spiking suspension to achieve a minimum concentration of MS2 in the field sample of 10 8 PFU/L).

To this same sample, spike 10 8 PFU of PhiX174. This number can be achieved by adding approximately 0.1 mL of a PhiX174 spiking suspension with a concentration of approximately 10 9 PFU/mL (may adjust the volume of the PhiX174 spiking suspension added based on the actual concentration of the spiking suspension to achieve a minimum concentration of PhiX174 in the field sample of 10 8 PFU/L). 3. Spike 10 7 GCMPN/ml of OC43 to 1100 ml of the field sample (the same sample that has been spiked with MS2 and PhiX174 and is used for measuring the native virus). This number can be achieved by adding approximately 1ml of an OC43 spiking suspension with a concentration of approximately 10 7 GCMPN/ml (may adjust the volume of the OC43 spiking suspension added based on the actual concentration of the spiking suspension to achieve a minimum concentration of OC43 in the field sample of 10 7 GCMPN/L).

Process and analyze the sample using the sample procedures that are used for the samples without the matrix spike with the exception that this sample will also SOP 2.2 be analyzed for MS2 and Phix174 using both culture and molecular procedures; and, for OC43 use molecular procedures only.

Laboratories are to report PFU in all dilutions where there are countable plaques (zero to 300 PFU per plate for male-specific (F + ) coliphage and zero to 100 PFU per plate for somatic coliphage. For too numerous to count plates, please enter TNTC in the comment section of the report associated with that dilution. Make the final calculation based on all dilutions with countable plaques (refer to equation in section 13.1.5 from EPA 1602). 6.

For enveloped viruses, report the concentration as determined from rt-qPCR standard curve.

Laboratory performance for the MS samples conducted for this study will be compared to the acceptance criteria in Appendix D of RFQ 4952.

Replace this step with the following: A 4 L raw wastewater sample will be collected by the wastewater treatment facility staff and will be delivered to the lab. The sample should be labeled with a unique sample number. The facility staff should record the unique sample number, facility name, sampler's name, location at sampling site, date, and time on a sample data sheet 9.2.

Procedure is same only the 4 L sample will not be filtered so there is no cartridge housing or intake/discharge module. The sample should be shipped cold (1-10 C) not frozen. 9.3.2

Labs will receive a 4 L sample (using a portion for measuring virus, a portion for protozoa, and a portion for phage). The samples will not be filtered, so the lab will not receive a cartridge filter.

Skip these steps. Instead complete the following modified concentration/purification procedure: 

Centrifuge the filter at 4000-5000 x g for 30 minutes or until the concentrate is reduced to less than 1 mL. c. Record initial and final volume. Resuspend concentrate and transfer to sterile 1.5 mL sterile tube. Store at 4 +/-3 C for up to 24 hours or at -80 C until extraction. Proceed to SECTION 13 (Molecular Analysis).

Slowly adjust pH of the remaining sample (approximately 1 L) for enteric virus analysis to 9.5 +/-0.1 using 1-3 N NaOH. Stir at room temperature for an additional 60 minutes, confirm pH is still in range after 30 minutes. 6.

Transfer into 250-or 500-mL centrifuge tubes. Centrifuge at 3,000 x g for 20 minutes (brake no more than 20%). 7.

Decant or pipet supernatant into 1 L container and record the volume. Discard pellets. 8.

Check pH of supernatant using pH meter and adjust to 7.2+/-0.2 using 1-3 N HCL. 9.

Add 52 g of Sodium chloride (NaCl) and mix/stir to dissolve then add 120 g PEG 8000and Mix by inversion or stirring for minimum 2 hours/ or up to 20 hours at 4 +/-3 C 10.

If necessary, transfer to appropriate centrifuge tube. Centrifuge at a minimum of 4,000 x g for 45 mins at 4 C (Brake at no more than 20%). 11.

Carefully decant and discard the supernatant. Invert tube over a paper towel for up to 30 seconds to ensure liquid removal from tube. 12.

Resuspend the pellet in 1-2 mL of cold PBS. Mix with pipet tip. Avoid making bubbles. Do not vortex. 13.

Quantitatively Transfer (using additional 0.5 mL cold PBS) the re-dissolved pellet to a 15 mL chemical resistant centrifuge tube 14.

Record the re-dissolved pellet final volume resulting from the previous step (designated Final Concentrated Sample Volume, FCSV) on the virus data sheet. 15. Add 4 mL (or twice the volume of the transferred volume if it is greater than 2.5 mL) of chloroform/butanol solution. Vortex and let stand for 5 minutes. 16 .

Centrifuge at minimum of 13500 x g for 15 minutes at 4 C 17.

Using a micropipette, transfer the top layer (the aqueous phase) to a sterile 15mL centrifuge tube (approximately 2 mL). Chloroform will be on the bottom. Avoid transferring chloroform, go slowly and do not slant tube while transferring. 18.

Record the weight of the 15 mL centrifuge tube before and after transfer. Record both and calculate saved volume. Record this volume (designated FCSV recovered after extraction) on the virus data sheet. 19 .

The pellet/concentrate can be held for up to 18 hours in refrigerator or frozen at -80 C for longer storage. Freezing and thawing can lead to virus losses so avoid multiple freeze/thaw cycles. 20.

A portion of the pellet/concentrate will proceed to nucleic acid extraction, a portion of the pellet/concentrate will be diluted and then proceed to the culture assays, and the remaining portion of the pellet/concentrate will be frozen for backup/archival purposes. a. 0.4 mL of the pellet shall be diluted to a total volume of 4 mL using cold PBS.

i. 1.35 mL of the 4 mL re-dissolved pellet/concentrate will be used for the enterovirus culture assay (called subsample 1) ii. 1.35 mL of the 4 mL re-dissolved pellet/concentrate will be used for the adenovirus culture assay (called subsample 1B) iii. 0.3 mL of the 4 mL re-dissolved pellet/concentrate will be used for the MS2 and PhiX174 culture assay (called subsample 1C) iv. The rest of the 4 mL re-dissolved pellet/concentrate will be frozen at -70 C for backup and archival purposes b. 1 mL of the pellet will be used for nucleic acid extraction (called subsample 2) c. The remaining pellet will use frozen at -70 C for backup and archival purposes (called subsample 3)

Proceed to Section 12 (with the addition of adenovirus, MS2, and PhiX174 culture) and Section 13 (with the addition of adenovirus, SARS-CoV-2, OC43, MS2, PhiX174 molecular). Section 12 and Section 13 may be completed in parallel. The 100-fold dilution is prepared by diluting 0.3 mL of the 10-fold dilution to a volume of 3.0 mL with cold PBS 12.1.2.4

The lab must perform these negative controls 12.1.2.5

The lab must perform these positive controls 12. 

Four dilutions of concentrate will be analyzed in duplicate for each coliphage type. As a result, nine double-agar layer plates will be required for each coliphage type: two plates per dilution (0.1, 0.01, 0.001, 0.0001) and one method blank plate.

Dilutions: a. Four dilutions will be needed: 0.1, 0.01, 0.001, 0.0001. Note: Subsample 1C (prepared in step 17.a.iii of the modified concentration/purification procedure; section 10 and 11, above) is already 0.1 dilution. Additional dilutions (beyond 0.0001) may be necessary. PBS (or PBW) is used as the diluent and is used to prepare the negative control. b. To prepare the dilutions, aseptically add 0.9 mL of PBS (or PBW) into each of four (or more) sterile dilution tubes. Label them as "0.01," "0.001," "0.0001," "method blank," etc. c. Add 0.1 mL of the subsample 1C (from step 17.a.iii of the modified concentration/purification procedure; section 10 and 11, above) to the tube of PBS (or PBW) labeled "0.01." d. Cap the tube and vortex for 5 seconds on a medium-high setting (if available) or until well-mixed. e. Add 0.1 mL of the well-mixed 0.01 dilution to a tube with 0.9 mL of PBS (or PBW) labeled "0.001". f. Cap the tube and vortex for 5 seconds on a medium-high setting (if available) or until well-mixed. g. Add 0.1 mL of the well-mixed 0.001 dilution to a tube with 0.9 mL of PBS (or PBW) labeled "0.0001." Cap the tube and vortex for 5 seconds on a medium-high setting (if available) or until well-mixed. h. Add 0.1 mL of PBS (or PBW) the tube labeled "method blank." Cap the tube and vortex for 5 seconds on a medium-high setting (if available) or until well-mixed.

Agar preparation: a. Place TSA molten agar with respective antibiotics in a 48-53 C water bath. The agar should remain molten in the water bath until ready for use. 18 Preparation of plates for enumeration of somatic coliphage: a. With the agar still in the water bath, aseptically inoculate tube containing nalidixic acid with 100 L of log-phase E. coli CN-13. b. Immediately add 100 L (0.1 mL) of subsample 1c (from step 17.a.iii of the modified concentration/purification procedure; section 10 and 11, above). c. Add 12-15 mL molten agar d. Mix the inoculum by rolling the tube briefly in palm of hand. e. Pour contents into one of the two petri plates marked "undiluted, E. coli  somatic." f. Duplicate analysis-Repeat Sections 5a through 5d for the duplicate. g. Repeat Sections 5a through 5e for each dilution volume.

Preparation of plates for enumeration of male-specific (F + ) coliphage-Repeat Section 5 using agar containing ampicillin/streptomycin and log-phase E. coli F amp 7.

Preparation of somatic coliphage method blank: a. With the agar still in the water bath, aseptically inoculate a tube containing nalidixic acid with 100 L of log-phase E. coli CN-13. b. Immediately add 100 L (0.1 mL) of TSB from the "method blank" dilution tube.

Add 12-15 mL molten agar. Mix the inoculum by rolling the tube briefly in palm of hand. c. Pour contents into a petri plate marked "method blank, E. coli CN-13, somatic."

Preparation of the male-specific (F + ) coliphage method blank-Repeat Section 7 using agar containing ampicillin/streptomycin and log-phase E. coli F amp . 9.

After the agar hardens, invert the plates and incubate for 16 to 24 hours at 36 C ± 1.0 C. 10.

Circular zones of clearing (typically 1 to 10 mm in diameter) in lawn of host bacteria after 14 to 24 hours of incubation are plaques. Count the number of SOP 2.2 plaques on each plate. Please note: The use of a light box to evaluate results is recommended. Record the results in the virus sheet.

Replace these steps with the following modified nucleic acid extraction procedure:

Follow manufacturer instructions in commercial kit (Zymo Quick-DNA/RNA Viral Kit # D7020) or equivalent.

Add 2 parts of Viral DNA/RNA Buffer to 1 part of sample and mix well (DNA/RNA Shield step is not necessary).

Transfer 700 μl of the mixture into one IIC-XL Column in a collection tube and centrifuge @ 10,000 x g for 1-2 minutes. Transfer the column into a new collection tube.

Reload the column with another 700 μl of the mixture and repeat centrifuge. Repeat until all of the mixture has been passed through the column.

Add 500 μl Viral Wash Buffer to the column, centrifuge for 30 seconds @ 10,000 x g and discard the flow-through. Repeat this step. 6.

Add 500 μl ethanol (95-100%) to the column and centrifuge for 1 minute @ 10,000 x g to ensure complete removal of the wash buffer. Carefully, transfer the column into a 1.5 mL nuclease-free tube. 7.

Add DNase/RNase-Free Water directly to the column matrix and centrifuge for 30 seconds @ 10,000 x g. 8.

The final extraction concentrate volume is 0.2 mL (enteric viruses) and 0.05 mL (0.1 mL in total) (coronaviruses) 9.

Refrigerate at 4 C for a maximum of 24 hours or <-20 C for up to one week until PCR analysis. Indefinite storage @ -80 C. 10.

Extract RNA from poliovirus, MS2, PHIX174, and OC43 stocks following the protocol above to calculate percent recoveries.

These two steps may be completed as a one-step reaction (i.e., reverse transcription should be completed in the same tube as qPCR); Each assay will be completed in triplicate. • For RT-qPCR 1-step assays: Refer run conditions for each primers/probe is specified in Tables 5 though 11 • For qPCR assays: refer to run conditions specified in Tables 10, and 12 • SARS-CoV-2 CDC N gene RT-qPCR (One step) assays: Run condition is specified in Table 14 • WHO E gene RT-qPCR (One step) assay: Run condition is specified in Table  15 Confirm (move if necessary) the threshold line lies within the exponential phase of the fluorescence curves and above any background signal.

Use the following equation to calculate genome copies per liter in the original sample rather than Eq. 5 in EPA 1615:

GCoriginal sample per L = Calculate genome copies per liter in the original sample GCassay = Genome copies measured from the qPCR assay Vnucleic acid extract = Volume of the concentrate after nucleic acid extraction (should be 0.2 mL) FCSV = Final concentrated sample volume (before chloroform extraction) (should be 2.0 mL) DF = dilution factor = the reciprocal of any dilution performed to compensate for inhibition (e.g., 10 and 100 for the 1:10 and 1:100 dilutions) Vassay = volume of the nucleic acid extraction used for each (rt)qPCR assay (should be 0.006 mL) Vpellet for molecular = volume of the re-dissolved pellet/concentration used for nucleic acid extraction (should be 1 mL) TSV = total sample volume (should be 1 L) 13.5.7 skip 13.6

The laboratory must use hepatitis G armored RNA as an inhibition control in all assays. The laboratory may option 1, 2, or 3 of 1615 as long as the inhibition control is run for all assays. 13 However, due to variability in stock Armored RNA Gene copies ( up to ±20%), it is highly recommended to determine the GC-MPN/ml titer of the stock armored RNA using the following steps; 13.7.1 Prepare 10-fold serial dilution (in TSM buffer) 13.7.2

Use the highest three dilutions (10, 100,1000) and 10 replicates per dilution. 13.7.3

Perform RT-qPCR and qPCR (section 13.5) using primers and probe. 13.7.4

Obtain GC-MPN/ml for Armored RNA using EPA most probable Number Calculator or equivalent. Change the calculator's "Number of Dilutions" to 3, the "Number of Tubes per dilution" to 10, and the "Dilution Type" to Standard 10-Fold Serial. For each stock, input the number of positive replicates from the highest dilution giving at least one positive replicate and from the next two lower dilutions.

For this project, a full standard curve will be required for every sample. It is not acceptable to use stored standard curves and calibrators. 14.0

While the information in this section provides good perspective, the acceptance criteria given in Appendix D of the RFQ will be used for this study instead of the acceptance criteria in EPA 1615 (for both matrix spikes and positive QC samples). Table 2 Not applicable Table 4 Standards for preparing the standard curve: Positive Control provided by IDT Kit is 2E+05 GC/ul or 1E+06/5ul is serially diluted to 1E+01 and used as standard curve. For 1-step: set up the thermocycler program and run with a setting of 1 cycle hold at 50 °C for 10 min, 1 cycle hold at 95 °C for 2 min, followed by 40 cycles of 95 °C for 10 sec, and 60 °C for 60 sec (capture fluorescence).

--------------------------------------------------------------------------------------------------------------------- 16, Revised

Use Option 1 if standards are prepared to correspond to 6 ul per reaction-Use Option 2 if standards are prepared to correspond to 5 ul per reaction volume. The purpose of this protocol is to outline the steps necessary to concentrate untreated municipal wastewater samples for microbial analysis. The scope of this protocol applies to small volumes (e.g., 250 ml) of untreated municipal wastewater and for detection of a wide range of microorganisms but has been specifically designed for analysis of SARS-CoV-2. As such, additional biosafety measures are required for processes that could generate aerosols from wastewater samples.

Upon receipt in the lab, samples will be stored at 4°C for no more than 72 hours from the start of sample collection (holding time subject to change as more data become available). Each sample will be amended with PBS and an human coronavirus (OC43) matrix spike and a small volume (0.2 ml) will be removed for direct nucleic acid extraction and analysis of the matrix spike and endogenous viruses of human fecal origin. The sample concentration steps consist of centrifugation, membrane filtration (0.45 µm) and ultrafiltation (30 kDa Centricon-Plus units). The products from each step (centrifugation pellet, membrane filters and ultrafiltration retentate) will be analyzed. Each sample will be processed in duplicate and will result in 4 products: unprocessed sample, pellet, filter, ultrafiltration retentate. 

To date, there are no recommended methods for concentrating SARS-CoV-2 from wastewater, thus creating a challenge for efficient recovery from sewage. Wastewater contains constituents that can readily inactivate virions, degrade genomic material and inhibit detection. Thus, holding times, sample stabilizers and other quality control metrics are being investigated and will be implemented as data are available.

All personnel must be current in mandatory laboratory safety training, including Hazardous Waste Management, Chemical Hygiene and respiratory protection courses. Personnel must also be aware of the biosafety guidelines for handling specimens likely containing SARS-CoV-2 and be certified to wear respiratory protection. The technique of first-time analysts must be reviewed by an experienced analyst prior to completing this SOP alone. During this review, the new analyst must demonstrate proficiency in completing this procedure alone which must be approved and documented by an experienced analyst/supervisor. Personnel must wear the required personal protective equipment (eye protection, lab coat, gloves and respiratory protection) while performing this protocol. 4. Obtain the samples in plastic bags for secondary containment from temporary storage at 2-8°C.

5. One at a time, transfer the sample to the BSC, remove the sample bottle from the plastic bag and wipe the outside of the bottle with 70% ethanol.

6. Invert the sample bottle 20 times to mix.

7. Using a sterile graduated cylinder, measure 225 ml and transfer to the appropriately labeled 250 ml conical tube.

8. Add 25 ml of 10X PBS and 1 ml of OC43 process control to each sample and invert sample bottles 10 times.

9. Remove 0.2 ml of each prepared sample to a labeled 1.5 ml tube for nucleic acid extraction. Tubes should be labeled with date, analyst's last name, SampleID and "before processing."

10. Balance the 250 ml conical tubes in the centrifuge cups with conical bottom cushions and safety caps using a dual-pan balance.

11. Centrifuge the samples at 3000 x g for 15 minutes at 10˚C to pellet the larger particulate matter. 23. Store the sample products (4 sample tubes per sample replicate: 1) before processing, 2) pellet, 3) filter, and 4) UF retentate) at -20°C.

24. Doff PPE appropriately.

A research notebook will be kept by each individual researcher generating or analyzing data. Each laboratory notebook will be used to record or reference research goals, hypotheses, assumptions, experimental data, interim summaries and conclusion. Experimental procedures, apparatus, and data will be recorded with sufficient detail such that another trained person could reconstruct the experiment.

The quality control procedures required to demonstrate successful performance of sample concentration includes the use of positive and negative controls. 

Nichole Brinkman, USEPA/ORD 07/20/2020

The purpose of this protocol is to outline the steps necessary to extract nucleic acids from unprocessed and concentrated municipal wastewater samples for microbial analysis by RT-PCR/PCR. The steps described here are adapted from the manufacturer's protocols (Qiagen A and B) .

Nucleic acids are indiscriminately extracted from virions and prokaryotic/eukaryotic/archaeal cells present in samples using commercially available kits. The Qiagen AllPrep PowerViral DNA/RNA Kit is used to extract nucleic acids from the unprocessed and ultrafiltered sample products and RNeasy PowerWater kit is used with the pellet and membrane filter sample products. The kits utilize the same buffers and silica-based strategy for chemical lysis, precipitation and purification of nucleic acids, but the pellet and membrane filter sample products require mechanical pressure through bead beating to facilitate release of nucleic acids using the RNeasy PowerWater kit bead tubes. Briefly, a small volume of Phi6 bacteriophage stock is added to all sample products to assess extraction efficiency, along with a lysis solution (PM1). The pellet and membrane filter sample products are bead beaded and then an inhibitor removal solution (IRS) is added to pellet organic material and any molecules that could interfere with PCR. A combination of solutions containing chaotropic agents and binding salts (PM3 and PM4) is added to facilitate RNA and DNA to adhere to a silica spin column. The sample lysate is added onto the silica-based spin column to bind nucleic acids followed by washes with alcohol-based solutions to purify RNA/DNA bound to the spin column. Nucleic acids are eluted from the spin column with RNase-free water. 

Standard laboratory PPE (i.e., laboratory coat, safety glasses/goggles, and gloves) is required. Nucleic acid extractions must take place in a biological safety cabinet (BSC). Special care must be taken in handling β-mercaptoethanol (CAS# 60-24-2), a volatile liquid that is toxic to the nervous system and can be absorbed through the skin and mucous membranes. β-mercaptoethanol storage container should be opened in a biosafety cabinet that vents to the outside, and all pipetting operations should be carried out in the biosafety cabinet. All solutions containing β-mercaptoethanol, isopropanol, ethanol, detergents, and the proprietary chaotrope should be disposed of appropriately.

To reduce the risk of potential contamination and/or degradation of nucleic acids during the processing of samples, the analyst should wear appropriate PPE and never handle samples or reagents with bare hands. Prior to and after extractions, samples should only be opened in a disinfected BSC. Where applicable, equipment (i.e., micropipettes) should be wiped with 10% bleach and should be used to disinfect bench top surfaces before and after use to degrade residual amplicons left on lab surfaces.

All personnel must be current in mandatory laboratory safety training. Personnel must also be aware of the biosafety guidelines for handling specimens likely containing SARS-CoV-2. The technique of firsttime analysts must be reviewed by an experienced analyst prior to completing this SOP alone. During this review, the new analyst must demonstrate proficiency in completing this procedure alone which must be approved and documented by an experienced analyst/supervisor. Personnel must wear the required personal protective equipment (eye protection, lab coat and gloves) while performing this protocol. 6. Make a solution of PM1 and β-ME (10 uL β-ME/1000 uL PM1) for all samples. Note that each pellet and Filter sample fractions require 1mL of PM1-β-ME, while the subsamples removed before processing and UF fractions require 600 ul of PM1-β-ME. 7 . Prepare the pellet sample fractions by resuspending each pellet in 1 mL of PM1-β-ME. Transfer the entire volume to a 5 mL PowerWater bead tube. Ensure all biomass is scraped off the sites; this may require forcefully pipetting up and down. Add 10 ul of the Phi6 stock to each sample tube.

8. Prepare the filter sample fractions by adding 1mL of PM1-β-ME to each 5mL PowerWater bead tubes that have filters. Add 10 ul of the Phi6 stock to each sample tube.

9. Secure the PowerWater bead tubes horizontally to a MO BIO Vortex Adapter. The tube caps should be oriented pointing toward the center of the Vortex Adapter.

10. Vortex at maximum speed for 5 minutes.

11. Centrifuge bead tubes at 4000 x g for 1 minute at room temperature.

12. Transfer all the supernatant using a 1mL pipette tip into a clean labeled 2 mL collection tube (provided in the kit) by placing the tip down into the beads and drawing as much volume as possible.

13. Centrifuge the tubes at 13,000 x g for 1 minute.

14. Avoiding the pellet, transfer the supernatant to the clean 2mL collection tube pre-loaded with 200uL of IRS. Continue to step 18 for processing all the sample products.

15. Prepare the 0.2 ml subsample removed prior to processing and the ultrafilter retentate by adding dd 10 ul of the Phi6 stock and 600 uL of PM1-β-ME directly into the sample tubes. 16 25. Turn off the vacuum and place spin filters into the spin filter collection tube and centrifuge at 13,000

x g for 2 minutes to remove any residual wash solution.

26. Place the Spin column into the appropriately labeled clean 2 mL Collection Tube.

27. Add 125 µL of RNase-Free Water to the center of the filter membrane. Allow the water to sit on the membrane for at least 5 minutes.

28. Centrifuge at 13,000 x g for 1 minute.

29. Remove spin columns and close tubes containing extracted nucleic acids.

30. Store extracts at -80C.

A research notebook will be kept by each individual researcher generating or analyzing data. Each laboratory notebook will be used to record or reference research goals, hypotheses, assumptions, experimental data, interim summaries and conclusion. Experimental procedures, apparatus, and data will be recorded with sufficient detail such that another trained person could reconstruct the experiment.

The quality control procedures required to demonstrate successful performance of sample concentration includes the use of positive and negative controls. Table 1 describes how controls will be assessed. 

This standard operating procedure (SOP) describes the amplification and quantitation of genomic targets using droplet digital PCR (ddPCR).

ddPCR can be used to quantify RNA and DNA targets of prokaryotes, eukaryotes, archaea and viruses in a variety of sample matrices, including, but not limited to, water, air and rubber surfaces. The use of this procedure is contingent upon sample preparation that releases RNA and/or DNA from cells or viral capsids.

The use of quantitative PCR (qPCR) to determine the concentrations of targeted microbes in environmental samples has become a standard tool used in microbiology because it is sensitive and specific for the intended microbial targets. The quantitative nature of qPCR relies on the linear relationship that exists between log10 target sequences in a sample and the number of thermal cycles needed to reach a defined threshold (often referred to as the cycle threshold) where fluorescence is detectable above background but is still increasing exponentially due to PCR amplification. Fluorescence can be produced either by the binding of intercalating dyes or by the cleavage of target sequence specific probes that both occur stoichiometrically with the generation of amplified target sequence fragments. Based on this relationship, standard curves of log10 target sequences vs. cycle threshold measurements can be generated from well characterized source material (standards) using a linear regression model and target sequences in unknown samples can be quantified by interpolation of their cycle threshold measurements on the standard curves. In this way, qPCR provides quantitation of unknown samples relative to known standards.

Despite the utility of qPCR in many environmental applications, limitations inherent in the linear regression approach can lead to inconclusive results such as when target concentrations of unknown samples fall outside of the dynamic range of the standard curve and when PCR inhibitors are present in the sample. In the former scenario, quantities of target sequences in unknown samples become inaccurate or are unable to be determined. While in the latter scenario, PCR inhibition directly affects amplification efficiency resulting in an underestimation of the true target sequence concentration in the sample.

Digital PCR (dPCR) utilizes the components of qPCR, but eliminates the need for a standard curve. Therefore, the disadvantages intrinsic to quantity estimates inferred from a curve are also eliminated. However, quantitation is still feasible and offers precision in quantity determinations beyond the capability of qPCR. In dPCR, samples are portioned into thousands of nanoliter sized PCR reactions such that each reaction contains zero or one or more DNA templates. After endpoint PCR amplification, each reaction is screened to determine whether amplification occurred. The number of positive and negative reactions is scored and used to Droplet digital PCR (ddPCR) uses an oil-based approach to partition the nanoliter reactions. This SOP describes the steps to perform ddPCR using BioRad's QX200 ddPCR system.

ADG -automated droplet generator BSC -biological safety cabinet BSL -biosafety level ddPCR -droplet digital PCR DNA -deoxyribonucleic acid PCR -polymerase chain reaction RNA -ribonucleic acid RT-ddPCR -reverse transcriptase-ddPCR PPE -personal protective equipment

Standard laboratory PPE for Biosafety Level (BSL) 1 microorganisms is required. This PPE consists of lab coat, safety glasses and gloves.

HASP# 2015-046 describes the health and safety considerations for conducting PCR. Use of the ddPCR reader in the post-PCR lab is covered under HASP# 2016-017.

PCR is a sensitive tool for detecting genomic targets in samples. To reduce the risk of potential contamination during the processing of samples, the analyst should wear appropriate PPE and never handle samples or reagents with bare hands. Prior to PCR, samples should only be opened in a BSC that has been sanitized with 10% bleach and UV prior to use. Where applicable, equipment (i.e., micropipettes) should be wiped with 10% bleach. After samples have been amplified by PCR, a BSC is not required for sample manipulation. However, 10% bleach should be used to disinfect bench top surfaces before and after use to degrade residual amplicons left on lab surfaces. Also, a unidirectional work-flow will be implemented to prevent cross-contamination of amplicons between labs. Negative PCR controls will be used to monitor potential contamination events during these operational procedures. Samples and master mixes containing enzymes should be kept on ice or in a cold block to maintain integrity/activity during PCR set up. 

Care should be taken when generating droplets in the manual mode. Air bubbles can cover the bottom of the well and result in 2500-7000 fewer droplets and poor data quality. They are difficult to see. To avoid creating air bubbles, use the pipetting technique described in detail in section 9 "Manual Droplet Generation," step 3. These techniques, ensures samples wet the bottoms of the wells so they are wicked into the microchannels (necessary for proper droplet generation).

PCR is an enzymatic reaction that can be disrupted if interfering substances are co-extracted and purified during sample processing. For best results, high quality DNA should be used in these procedures.

The techniques of first-time analysts must be reviewed by an experienced analyst prior to completing this SOP alone. During this review, the new analyst must demonstrate his/her ability to complete this procedure alone which must be approved and documented by an experienced analyst/supervisor in the analyst's laboratory notebook. 

Preparation of Positive (RT-)ddPCR Controls for the FAM and VIC/HEX Channels 1. Identify material to be used as a positive control. This can be a genomic extract of the organism of interest or a synthetic construct, like a minigene containing the targeted genomic sequence.

2. Determine the concentration of the DNA stock to be used a positive control.

3. Dilute the positive control stock to 3.2 x 10 4 genomic copies/ul in a volume sufficient to prepare the desired number of aliquots. This quantity equates to approximately 10 copies of the ddPCR target per droplet, assuming an average of 16,000 droplets per reaction.

4. Prepare 25 µl aliquots of the positive control and store at -80°C.

1. Identify material to be used as an exogenous internal amplification control. This can be a genomic extract of a specific organism or a synthetic construct, like a minigene containing the targeted genomic sequence.

2. Determine the concentration of the DNA stock to be used an exogenous internal amplification control.

3. Dilute the exogenous internal amplification control stock to 1.3 x 10 4 genomic copies/ul in a volume sufficient to prepare the desired number of aliquots. This quantity equates to approximately 1.6 copies of the ddPCR target per droplet, assuming an average of 16,000 droplets per reaction. Preparation of (RT-)ddPCR Reactions

Bleach PCR hood in clean room. Turn on UV for at least 15 min.

Wipe the barrels of all micropipettors to be used with 10% bleach.

In PCR hood, prepare the ddPCR or RT-ddPCR mixes, examples are shown in Section 14 Tables 1-2 below. Move to DNA lab.

Bleach Biosafety cabinet in DNA lab. Turn on UV for at least 15 min. Wipe the barrels of all micropipettors to be used with 10% bleach.

Obtain samples, positive controls and internal amplification control aliquots from the -80°C freezer. Table 3 with 10 mM Tris-HCl, pH 8.5.

Obtain an Eppendorf 96-well twin.tec PCR plate (these are the ONLY plates that fit in the ADG and reader).

Dispense 18 µl of the ddPCR/RT-ddPCR master mix into the 5 NTC wells as outlined in Table 3 .

To the ddPCR/RT-ddPCR negative control (NTC) wells, load 7 µl of 10 mM Tris-HCl, pH 8.5 to the corresponding wells of the plate as indicated in Table 3 .

To the remaining ddPCR/RT-ddPCR master mix, add 2 µl of the exogenous internal amplification control (1.3 x 10 4 genomic copies/ul) for the remaining reactions: 2 x (100-5) = 190µl.

Dispense 20 µl of the ddPCR/RT-ddPCR master mix with the exogenous internal amplification control to the remaining reactions in the 96 well plate as indicated in Table  3 .

Add 5 µl of the appropriate positive control sample to the positive control wells as indicated in Table 3 .

Add 5 µl of the appropriate sample to the wells as indicated in Table 3. 14.

If using the ADG to make droplets, seal the plate with the appropriate foil seals and PX1 PCR Plate Sealer. If using the manual Droplet Generator to make droplets, seal the plate with Microseal-A. Mix plate thoroughly by vortexing briefly, followed by centrifugation at 500 x g for 15 sec.

Allow the reactions to equilibrate to room temperature for about 3 minutes before loading into the droplet generator.

• The QX200 droplet generator prepares droplets for up to eight samples at time. Droplet generation takes ~ 2 minutes for each set of 8 samples (~30 minutes for a 96-well plate).

• All 8 sample wells in the DG8 droplet generator cartridge must contain sample (or 1X buffer control), and all 8 oil wells must contain droplet generator oil.

• Do not load sample or oil into the DG8 cartridge unless it is inserted in the holder. 

Using a multichannel pipet, fill each oil well (bottom row) with 70 µl of DG oil from the reagent reservoir.

Hook the gasket over the cartridge holder using the holes on both sides. The gasket must be securely hooked on both ends of the holder; otherwise, pressure sufficient for droplet generation will not be achieved. c. Slowly draw 40 µl of droplets into the pipet tip (should take ~5 sec and ~5 µl air is expected); do not aspirate >40 µl as this causes air to percolate through the droplets. Pipet slowly. Apply a stable resistive force to the plunger to draw and aspirate droplets smoothly into and out of pipet tips.

d. To dispense droplets into the 96-well plate, position the pipet tip along the side of the well -near, but not at, the bottom of the well -and slowly dispense droplets (~5 sec). e. To prevent evaporation and contamination with particulates, cover the plate as you work. To cover the plate, set the tip box lid or a piece of foil over the plate.

Once droplets are removed, press the latches on the DG8 cartridge holder to open it. Remove the empty DG8 cartridge and discard it. 

Automatic Droplet Generation and ddPCR 1. When powering on the Automated Droplet Generator (ADG), you will see a startup screen while the instrument powers on and performs a self-check. Please note that the door will automatically close.

2. If the instrument deck is empty, the indicator lights on the deck of the ADG should be off, indicating that no consumables are present. The corresponding areas of the touch screen will be gray. If consumables were present in the instrument when power was lost or disconnected, an error message will appear prompting you to check and reset the consumables if necessary. The cartridges, gaskets, tips and plates are all single-use consumables and should be discarded in the biohazard waste after use. If the consumables in the instrument are of questionable use after power loss, please remove and discard.

3. Bring the ADG out of idle mode by touching the screen. c. The plate name and plate notes are optional; touching the files will bring up a keyboard on the screen. Click OK when done.

6. Based on the number of columns selected in the previous step, the consumable icons on the screen will begin to blink yellow to indicate where new consumables need to be loaded into the instrument.

a. If the blinking yellow icon displays Load on the screen, remove the previously used consumable (if applicable) and load a new consumable into the designated are of the instrument.

b. If the icon remains gray on the screen, that consumable is not needed to complete the currently configured run.

7. Open the door on the ADG instrument by lifting up on the handle at the front to the instrument. The electronic braking system will assist you in this task and prevent the lid from closing accidentally. Note: the ADG door will close the preserve HEPA-filtered b. The lights on the DG32 plate holders will change from yellow to green when the DG32 cartridges are inserted correctly. If a light remains yellow, try repositioning the plate in a different orientation.

c. As the lights turn green on the deck, the corresponding icons on the touch screen will go from blinking yellow to solid green and Ready will be displayed. c. The lights on the tip box holders will changed from yellow to green when the tip boxes are inserted correctly.

d. As the lights turn green on the deck, the corresponding areas of the touch screen will go from blinking yellow to solid green, and "Ready" will be displayed. c. The light on the Sample Plate holder will change from yellow to green when the plate is inserted correctly. If the light remains yellow, try repositioning the plate in a different orientation.

d. As the light turns green on the deck, the corresponding icon on the touch screen will go from blinking yellow to solid green, and Ready will be displayed.

e. Note that a sample plate is required for every run, regardless of the number of columns selected.

11. To load the Droplet Plate assembly:

a. The cooling block should be placed in a -20C freezer for at least 2 hours before configuring a run on the ADG instrument and inserting into the instrument. The block goes from a pink color at room temperature to a dark purple color when properly cooled.

b. Remove the cooling block from the freezer and place into the front right plate holder, labeled on the screen as Droplet plate. The holder is keyed for proper orientation of the cooling block. The block should be a dark purple color, indicating that it is at the proper temperature. If the block is pink, it has warmed up and should not be used.

c. The light on the instrument will change from yellow to green when the block is interested correctly. If the light remains yellow, try repositioning the block in a different orientation.

d. As the light turns green on the deck, the corresponding area of the screen will go from blinking yellow to solid green, and Ready will be displayed.

e. Place a clean 96-well PCR plate for droplet collection into the cooling block accessory. The cooling block is also keyed for proper orientation of the plate.

f. A clean droplet plate is required for every run, regardless of the number of columns selected. Once generated, the droplets will be dispensed into the sample plate orientation as the ddPCR reactions were taken from the sample plate.

12. To load the ADG Oil into the instrument: b. Select the type of ADG oil that was loaded into the instrument by touching the droplet for either Probes or EvaGreen oil, depending on the type of assay being used. The droplet you select will turn blue; touch OK to set the oil type.

c. The oil level icon on the screen will turn blue and display the current oil level of the bottle. They system will display the oil type at the bottom left of the screen as well.

d. If a bottle of ADG oil was previously loaded, you may be prompted to confirm the type of oil currently loaded into the instrument.

e. If the last plates were run on the ADG with a different oil type than the one being currently loaded and selected, the instrument will perform a small volume purge of the oil through the delivery system and into the oil waste reservoir. The total run time will be a few minutes longer when this occurs, but droplet generation will not be impacted.

13. Once all of the consumables are loaded and the corresponding lights are green on the deck and touch screen, a blue Start button will appear at the bottom right of the screen. Touching Start will bring up a confirmation window indicating the type of Droplet Generation Oil loaded, the number and orientation of columns selected for droplet generation and any plate name and details entered during configuration of the sample plate.

14. Once you have confirmed the plate setup, touch the Start Run button to being droplet generation. The door will automatically close at the beginning of the run and must remain closed during the run. Opening the door before the Droplets Ready message appears may cause the instrument to terminate the run and samples to be lost. 15 . After a brief initialization the ADG will display a countdown timer on the screen with time remaining until the plate of droplets is ready. No additional action is needed until the plate is ready. Thin initialization can take 1-5 min, depending on whether the oil type has been changed or not. 16 . Once the plate of droplets is ready, the screen will display a finalizing window followed by a blue Droplets ready message with a timer showing time elapsed since complete. The droplet plate at the front right corner of the instrument will be illuminated blue. The corresponding icon on the touch screen will also pulse blue… the door on the instrument will unlock and the droplet plate can be removed. Please wait to remove the oil bottle as noted on the screen; the unused oil is being returned to the bottle. a. In the "Name" field of the Sample well editor, enter the SampleID.

b. In the "Experiment" field of the Sample well editor, select ABS.

c. In the "Supermix" field of the Sample well editor, select ddPCR Supermix for Probes (no dUTP) or One-Step RT-ddPCR Kit for Probes. 

i. In the "Name" field of the Target 1 well editor, enter the assay target ii. In the "Type" field, select Ch1Unknown, Ch1 Positive or NTC.

e. Define Assay 2 (channel 2, the VIC/HEX channel) in the Target 2 box:

i. In the "Name" field of the Target 2 well editor, enter the exogenous internal amplification control assay target ii. In the "Type" field, select Ch2Unknown, Ch2 Positive or NTC.

f. When done, click APPLY or OK to save the information.

8. Save the file using the following format: "YYYY-MM-DD_TCR_PCRX", where YYYY-MM-DD is the date of the ddPCR run and PCRX is the consecutive number of PCR plates run for this sample set.

9. Click RUN. Up to 1 minute later, a green circle appears next to the abort button and flashes periodically to indicate the run is in progress. Active and analyzed wells are also highlighted in green in the plate map.

10. When droplet reading is complete, all four indicator lights are solid green. Open the door and remove the plate holder from the unit. Remove the 96-wel PCR plate from the holder and discard it.

11. Save data files to L:\Lab\Lablan\MCEARD_digitalPCR\dPCR\Brinkman.

12. Use D-SED-EFAB-015-SOP-01 "Quantitative Analysis of ddPCR data" to assess positive and negative droplet populations based on droplet fluorescence and to calculate copies of genomic targets and internal amplification control in each sample.

The data output from the QuantaSoft software is a directory of files that includes files containing fluorescence data of every droplet detected in the 96-well plate and QuantaSoft analysis of the droplet data. The entire directory will be copied to the LabLan for backup and access for further analysis, as described in D-SED-EFAB-015-SOP-01.

The quality control procedures required to demonstrate successful performance of (RT-)ddPCR include the use of positive and negative controls. To ensure quality of data collection during PCR, a negative control consisting of the buffer used to dilute samples will be used. This should result in baseline fluorescence amplitude levels for every droplet detected. A positive control for (RT-)ddPCR consists of DNA containing the targeted amplicon, either from extracts of organisms or synthesized DNA constructs. This control will contain 10^5 copies of the target per reaction, resulting in an average of 10 copies per droplet and amplification in 100% of droplets.

If the (RT-)ddPCR negative controls result in droplets with fluorescence amplitude levels indicating amplification or the PCR positive controls result in the less than 100% positive SOP Title: Droplet Digital PCR (ddPCR) Analysis of Genomic Targets droplets, the amplicons will be discarded and the (RT-)ddPCR will be repeated.

The results of the quality control procedures will be documented in the analysts' notebook. All QC failures will be reported to the project lead. A discussion of the overall QC procedures and results will be described in the manuscript.

This SOP was adapted from BioRad documents for the QX200 Droplet Digital PCR System, which can be found at http://www.bio-rad.com/en-us/product/qx200-droplet-digital-pcrsystem?tab=Documents 

In a preliminary analysis of the major potential exposure routes to human fecal matter, the routine detaching of the internal collection tubes from the sample container to the cooler opens the most potential for exposure to small amounts of fecal matter. For more rare and catastrophic events, drop and spill is highlighted.

Mitigation for the routine risk of exposure includes the use of proper PPE, the use of 70% ethanol, and the immediate spike of the Tween-20 surfactant on the arrival in the lab. No sample properties or assays are allowed on the pre-surfactant treated raw wastewater. Mitigation of potential crash events include the usage of triple barriers (both in the design of the sampler and the transportation method) and the maintenance of on onsite spill cleanup kit (mentioned above).

Required training includes on-site sampling, but also EHS specific training These students will work in solo alternating shifts. However, they will not be allowed to work in the lab alone. Either the graduate student researcher, postdoctoral researcher, or principal investigator must be onsite and within the lab, following social distancing guidelines.

Centrifuge the Sample to Remove Debris 1. Pipette transfer equally-weighted volumes (50-mL) of the Tween-20 treated sewage to 50-mL conical tubes; weight to ensure the balance of the swing-bucket centrifuge rotor; 2. On the Tween-20 treated sewage, centrifuge 50 mL of the media at 10,000×g for 10 minutes at 4°C (or longer at slower speeds; Sorvall 8-R). Continue with the supernatant, discarding the pellet. NOTE: On a rotating schedule, extract from the pellet to ascertain virus lost.

1. Set up Concentrating Pipette (CP) as instructed in Section 4 of the CP Select User Guide. 2. Insert a Concentrating Pipette Tip (CPT) and select a menu protocol as instructed in Section 5.2 of the CP Select User Guide for the chosen CPT type. 3. Lower the CPT into the sample. 4. Press "Start Run" on the user screen. 5. When the entire sample has been processed the CP will stop. 6. Place a clean final sample container under the CPT. The menu screen will prompt you to press "Elute". SOP 2S.5 3 7. Press "Elute". The sample will dispense from the pipette tip into the sample container. 8. The sample is ready for subsequent sample preparation and analysis steps.

EXCESS MEDIA DISPOSAL. Any excess sample will be inoculated with a high-concentration of common dish soap, let stand for >20 minutes in a fume hood, and disposed down the drain. This process will return the material to an EPA regulated and appropriate disposal route. This procedure will be required to receive approval from EHS.

The guidelines below are adapted from the manufacturer's manual

• Perform all steps at room temperature (20-25°C) unless otherwise noted.

• Use cold TRIzol™ Reagent • Wear disposable gloves while handling reagents and RNA samples to prevent RNase contamination from the surface of the skin; change gloves frequently, particularly as the protocol progresses from crude extracts to more purified materials.

• Use RNaseZap™ RNase Decontamination Solution (Cat. no. AM9780) to remove RNase contamination from work surfaces and non-disposable items such as centrifuges used during purification.

• Ensure that all materials that come into contact with TRIzol™ Reagent are compatible with phenol, guanidine isothiocyanate, and chloroform.

Resuspend RNA Make sure to use appropriate tubes and tips for this RT-qPCR.

From Gertjen Medema's KWR SOP wastewater SARS-CoV-2 RNA assays "Quantification of N1, N2 and N3 specific assays can be performed using four 10-fold dilutions (ranging from 1.0E+02 to 1.0E+05 copies per reaction) of the 2019-nCoV_N_Positive Control plasmid DNA from IDT (Leuven, Belgium) with specified concentrations as calibration suspension. Evaluate the standard curve parameters: PCR efficiency should be 80% and 105%, correlation coefficient R2 should be 0.9."

Quantification of E and F+ are run against dilutions of a gel-purified RT-PCR products run WITHOUT probe.

Quantification of BCoV is run against dilutions of a reference controlled purified RNA extraction. 3. Working on ice, add the components directly to each well of an optical reaction plate. 4. Cover the reaction plate with an optical adhesive cover and invert the plate 3-5 times, making sure that the contents of the wells are moving back and forth between the seal and the bottom of the wells to ensure proper mixing. a. IMPORTANT! The TaqPath™ 1-Step Multiplex Master Mix is a 4X formulation and is more viscous than most master mixes. Ensure that all of the components are thoroughly mixed in all the wells before proceeding. It has been observed that inverting the plate gives more uniform mixing across the reaction plate than vortexing. 5. Centrifuge the plate at 150 × g (1000 rpm) for 1 minute to collect the contents at the bottom of the wells and eliminate air bubbles.

Run the plate on an Applied Biosystems™ real-time PCR instrument. See the appropriate instrument user guide for detailed instructions to program the thermal cycling conditions or to run the plate. We will be using a QuantStudio3 

A dedicated lab space in the Engineering Center, ECSL 1B11, may be made available to setup a temporary lab unit SOP 2S.5

1

Kjellerup Lab's Internal QA/QC Officer: Devrim Kaya, Ph.D.

1) Centrifuge:

1. Prepare duplicate samples of each wastewater sample for procedure below 2. Add BRSV (our lab matrix spike): for WRF experiments: I added 34 and 10 uL of BRSV in triplicate samples at the sample prep step (to 30 mL of samples that is step 2 below), and RNA extraction step (to 0.25 mL that is used for RNA extraction step, Section B, step 1, below), respectively. 3. Take 30 mL of raw wastewater samples into a sterile 50 mL falcon tube (mark outside/upper part or the falcon tube where the pellet would have more force and accumulate). 4. Centrifuge at 3400 g with swinging-bucket centrifuges (use adapters for falcon tubes) for 15 min at room temperature to remove sediment and large particles 5. Carefully remove supernatant without disturbing the pellet (pellet should be visible). 6. Pour supernatant carefully from the side of the tube opposite to the pellet into a new 50 mL falcon tube. 7. Keep the falcon tubes with pellets at 4°C if can't process immediately, resuspend pellet with RNAse free water (tot.

vol. 1 mL) and vortex the sample for 15 sec, this is enough to fully dissolve the pellet. Vortex also horizontally on the side that you expect to have the pellet. Be consisted with the choice of medium and write down final sample volume (pellet+medium). 8. Transfer resuspended pellet into 2 ml RNase-free tubes and store the samples up to 72 hrs at 4°C if can't process immediately, for long term store at -80°C/-20°C. 9. For concentration of supernatant (step 5) continue with Ultrafiltration Method (UF) methods described below

The supernatant coming from centrifuge part (aqueous phase containing virus particles) can be further concentrated by using ultrafiltration method through Amicon-15 centrifugal filters with a molecular cutoff of 100kDa (Merck Millipore) following manufacturer's protocol.

Amicon ® Ultra 100K device -100,000 MWCO (MilliporeSigma, cat no: UFC910024, 100,000 Da)

Add up to 15 mL of sample (total of 2 loads) 2. Place capped filter device into centrifuge rotor; counterbalance with a similar device. 3. When using a swinging-bucket rotor, spin the device at 3400 × g (maximum 4000 x g) for approximately 15-60 minutes (each load about 15 min).

Take concentrated sample into RNase free Tubes (2ml) and add RNAse free water into the bottom of the filter device and withdraw the sample using a side-to-side sweeping motion to ensure total recovery, total sample volume should be 1 mL.

Store samples at -20C/-80C for long-term storage, keep them at 4C if you will process (RNA/DNA extraction) them in 24-48C Note: 1) To recover the concentrated solute, insert a pipettor into the bottom of the filter device and withdraw the sample using a side-to-side sweeping motion to ensure total recovery. The ultrafiltrate can be stored in the centrifuge tube. 2) For optimal recovery, remove concentrated sample immediately after centrifugation.

Clean and decontaminate all work surfaces, pipette, centrifuges and other equipment using RNAZap or 10% freshly prepared bleach prior to use.

• Use RNase-free Tips, Tubes, and H2O.

• Clean and decontaminate all work surfaces, pipettes, centrifuges, and other equipment prior to use.

• Decontamination agents should be used such as 5% bleach, 70% ethanol, and DNAzap or RNase AWAY to minimize the risk of nucleic acid contamination. 2 All centrifugation steps should be performed between 10,000-16,000 x g (did at 12,000 x g). Follow manufacturer procedure: briefly: 1. Take 0.25 mL of concentrated sample in to clean RNAse free 2 mL Eppendorf tube 2. Add 600 uL RNA Lysis Buffer to the sample 3. Add 1 volume ethanol (95-100%) to the sample in RNA Lysis Buffer (1:1). Mix well. 4. Transfer the mixture to a Zymo-Spin TM IIICG Column 1 (green) in a Collection Tube and centrifuge for 30 seconds. Discard the flow-through. 5. Add 400 μl RNA Prep Buffer to the column and centrifuge for 30 seconds. Discard the flow-through. 6 . Add 700 μl RNA Wash Buffer to the column and centrifuge for 30 seconds. Discard the flow-through. 7. Add 400 μl RNA Wash Buffer and centrifuge the column for 2 minutes to ensure complete removal of the wash buffer. Transfer the column carefully into an RNase-free tube (not provided). 8. Add 100 μl DNase/RNase-Free Water directly to the column matrix and let it sit at RT for 1-2 min and centrifuge for 30 seconds. 9. The eluted RNA can be used immediately or stored at -70°C. 

• Mix well, denature mix (sample RNA/primer) 70C denature for 5mins and then cool down at 4C forever (till next step) or immediately on ice for 2 mins, centrifuge briefly. • After addition of the reagents, mix reaction mixtures by pipetting up and down. Do not vortex.

• Centrifuge for 10 seconds to collect contents at the bottom of the tube, and then place the tube in a cold rack.

• Dispense M2 into each well containing M1+RNA, so now the total rxn volume is 25 uL.

• Incubate the samples at 42C* for 1hr.

• Inactivate the enzyme at 70°C for 20 minutes

• Thaw the TaqMan® Fast Advanced Master Mix (Applied Biosystems cat no: 4444557) on ice, then mix thoroughly but gently. Table 1 for determination of primer/probes and volumes for N1, N2, BRSV, or OC43. Check Table 2 -4 for each target of interest (e.g., N1, N2, OC43 or BRSV)

• Vortex M3 briefly to mix • Centrifuge briefly to bring the reaction mix to the bottom of the tube and eliminate air bubbles.

• Set up reaction strip tubes or plates in a 96-well cooler rack.

• Dispense 17 µL of each master mix into the appropriate wells (of an optical reaction plate)

Nucleic Acid Template Addition 1) Gently vortex nucleic acid sample tubes for approximately 5 seconds.

2) Centrifuge for 5 seconds to collect contents at the bottom of the tube.

After centrifugation, place extracted nucleic acid sample tubes in the cold rack. SOP 2S.6 4 4) Add cDNA template, 3 µL, or Nuclease-Free Water for NTC, to each well of the specific assay that is being tested. Carefully pipette 3 µL of the first sample into all the wells labeled for that sample. Keep other sample wells covered during addition to prevent cross contamination and to ensure sample tracking. Change tips after each addition 5) Change gloves often and when necessary to avoid contamination. 6) Repeat steps #4 and #5 for the remaining samples • Seal the reaction plate with optical adhesive film, then centrifuge briefly to bring the PCR reaction mix to the bottom of the well and eliminate air bubbles. • Apply a compression pad to the plate, if required by your real-time PCR system.

• Set up a plate document or experiment file on the thermocycler using the following conditions for BRSV and see Table 4 for N1 and N2 and 

Standard concentrations that are used to make calibration curve are shown in red. To make dilutions for the RT-qPCR standard curve, use the following -2019-nCoV_N_Positive Control (#10006625) -ScaI-HF from New England Bio #R3122S -Prepare enzyme reaction as detailed above.

-Incubate reaction at 37°C for 30 min (and no more than one hour) -Inactivate enzyme at 80°C for 20 min.

-Plasmid concentration (200,000 copies/uL) diluted to 40,000 copies/uL in final solution. Notes: -Our SARS-CoV-2 Control Plasmid (4,012 bp) comes at a concentration of 200,000 copies/uL -To adjust the digest protocol, we will use 5 units of enzyme at one hour (no more than one hour, as this is a HF enzyme and could result in erroneous cutting) -Dilute enzyme in 1X CutSmart Buffer to 5 units/uL -Enzyme should not exceed 10% of the reaction volume (5 uL) -The DNA sample should be no more than 25% of the reaction volume, according to NEB. To make dilutions for the RT-qPCR standard curve, use the following 

Centrifuge for 10min at 1500rpm.

Filter the 500mL wastewater supernatant through a 0.45μm pore size, 47mm diameter negatively charge HA membrane (HAWP04700; Millipore) via the filtration apparatus.

Re-suspend in 1mL wastewater supernatant.

Extract the RNA by using the Qiagen QIAamp® Viral RNA MiniKit (Cat# 52906) as per manufacturer's instruction. 

Use 2019-nCoV_N1 primer/probe mix, 2019-nCoV_N2 primer/probe mix, and Quantabio qScript XLT One-Step RT-qPCR tough Mix as described in the CDC protocol.

All RT-qPCR reactions were performed in triplicate.

For each qPCR run, a series of three positive and negative controls were included.

A known concentration of Oncorhynchus keta (O. keta) was processed to obtain the Ct value as reference point (as according to EPA Method 1611.1 protocol; April 2015).

If the Ct value of the sample increases compared to the reference point then the sample is considered to have PCR inhibitors.

All RNA samples were stored at -80C and subjected to RT-qPCR analysis within the same day after RNA extraction.

A reagent blank and an extraction blank were tested to ensure no carryover contamination occurred during RNA extraction. 

Purpose:

1. To outline the standard protocol for filtering 2019_nCoV virus from water samples for downstream analysis. 2. To incorporate matrix-spike-in samples for calculating virus recovery.

This protocol only applies to quantitative COVID-19 testing of water samples. This protocol does not include BSL2 work guidance.

Laboratory personnel who are authorized to work in BSL2 lab.

Note: a set of equipment designated for the BSL2 lab should not be taken out without thorough decontamination:

• Biosafety cabinet (BSL2 hood)

• Funnels with HA membrane options: 

• Make sure to clean the BSL2 hood working surface each time before starting a filtration batch. • Always wear clean gloves to take out unused funnels.

• Make sure the lid of the filtration funnel is always closed unless pouring in a water

sample. Only open one lid at a time. • NPEC shall be prepared with PCR-grade water.

• Wipe manifold holder with 10% bleach after filtration and before used for a different sample (the matrix spike for the same sample is not considered as a different sample). • Always ensure enough 100% ethanol for complete forceps flaming.

• Decontaminate pipettes and markers in the BSL2 hood regularly with 10% bleach and 70% ethanol.

Section 1: Filtration Preparation (outside BLS2 lab) 1. Turn on the water bath to warm up to 55C. Incubate buffer PM1 bottle at 55C for 10min to dissolve any precipitation. 2. Label the PowerBeads bead tubes (Qiagen) for samples and NPEC. Label a snap-cap 1.5ml tube for positive control "VS POS" sample. 3. Outside the BSL2 lab, prepare the lysis buffer. Fresh lysis buffer needs to be prepared before each filtration batch. Calculate the total number of samples (n), and prepare PM1 with beta-mercaptoethanol (2-Me) lysis buffer: a. Lysis buffer volume per filter sample: 700ul. b. Lysis buffer volume for VS POS sample: 600ul. c. Total volume of PM1: (n+1) * 700ul. (warm and clear, in a 5ml tube or 50ml tube depends on total volume) d. Add (n+1) *7 ul of 2-Me to PM1. e. Mix by inverting the tube several times. Section 2: Filtration methods selection and pH adjustment (inside BSL2 hood wearing PPE).

1. Depending on the turbidity of the water sample (may need to open the lid to look into the bottle), one needs to use his or her best judgment on how much water sample to filter and which method to choose from. One will gain enough experience with time, but here is a general reference table to follow. a. For samples to be processed with CF, invert the water bottle several times and pour into 2 or 4 pre-labeled 50ml conical tubes (see Section 3 below) b. For samples to be processed with DF of 50ml or 100ml, invert the water bottle several times and pour 200ml into a 250ml bottle. c. For samples to be filtered for more than 100ml, adjust the pH in the original 500ml water bottle. No need to pour out. 3. Samples must be titrated to pH3.5 by 2N HCl. Make sure the pH test is fairly accurate and not go down to 3.0. Record the volume of water and HCl used for future reference. 4. After pH adjustment, label the bottle or tube with "pH3.5". Incubate for a minimum 10min

(write down the time on the filtration bench sheet will help tracking the time) and shake vigorously before pouring that water sample into a funnel. 5. After pouring each sample into the funnel, make sure to close the lid to prevent cross contamination. 6. Filter the sample at ~60 psi for less than 45min. 7. DO NOT use PCR-water or PBS to rinse the bottle because of the pH difference. 8. After filtration, fold the membrane and store it in a bead tube containing 700ul Lysis Buffer. Invert the tube several times to ensure complete membrane coating. Swirl the pellet at the bottom of the 50ml conical tube in residual liquid, and pour them into a 5ml tube. For CF 100ml samples, combine pellets from two tubes into one 5ml tube. 5. Centrifuge the 5ml tube at maximum speed 7,830rpm x 10min to completely precipitate the pellet. 6. Use a P1000 pipette to take out liquid from the 5ml tube and add it back to the sample tube or bottle. 7. Adjust the pH of the supernatant, label the bottle or tube with "pH3.5". Incubate for 10min, and filter through an HA membrane. Note that addition of the matrix spike is done after pH adjustment to the supernatant, prior to incubation, so the pellet would not contain a spike. 8. While waiting for filtration to finish, add 700ul Lysis buffer to the pellet. Cut the tip of a P1000 tip with clean scissors. Resuspend the pellet with the cut-tip by pelleting up and down several times and transfer the suspension to a pre-labeled bead tube. Be careful that if the tip is stuck, it could create vacuum force and splash the sample during the dispensing step. 9. After all the supernatant has been filtered through the HA membrane, fold the membrane and put it in the same bead tube containing resuspended pellets. Invert the tube several times to ensure complete membrane coating.

Section 4: Matrix-spike-in samples (inside BSL2 hood wearing PPE) 1. After sample pH adjustment, take out one stock of 1:10 dilution of SARS-CoV-2 heat inactivated culture fluid aliquot from -80C freezer. Make a 1:1000 dilution with 1xPBS by adding 2ul of 1:10 viral fluid to 198ul PBS. 2. Add 2ul into the same filtration volume as the non-spiked sample.

a. For CF 50ml, you can add the 2ul 1:1000 viral dilution to the supernatant tube "S", and label the tube clearly with "+VS". b. For CF 100ml, after pouring out 100ml water for un-spiked sample filtration, add 2ul 1:1000 viral dilution to the remaining 100ml water in the 250ml bottle. And label the bottle clearly with "+VS". c. For CF >100ml, after pouring out water for un-spiked sample filtration, pour out the same amount of water into a 250ml blue-cap bottle. Add 2ul 1:1000 viral dilution to the bottle, and label the bottle clearly with "+VS". 3. Mix well by shaking the bottle vigorously. Note that addition of the matrix spike is done after pH adjust, prior to incubation. Incubate for a minimum 10min before filtration (writing down the time on the filtration bench sheet will help tracking the time). Note that for CF 50ml, the un-spiked sample and matrix-spike sample will have the same incubation time frame. 4. After pouring each sample into the funnel, make sure to close the lid to prevent cross contamination. 5. Filter the sample in the same way as the un-spiked sample. 7. Slowly pour aliquots of 30 -60 mL from each sample onto the middle of their respective filter. As much volume as possible, up to 60 mL, is preferred, but clogging of the filter usually determines the volume that can be filtered in a reasonable amount of time.

8. After the liquid volume has been filtered, shut the vacuum off. Remove each HA filter with a tweezer, fold in half with the solids on the inside, roll the filter up and place into a 2 mL beaded microcentrifuge tube containing 1 mL of DNA/RNA Shield reagent (to inactivate the virus and prevent RNA degradation).

2

All personnel involved with nucleic acid extraction and quantification should adhere to BSL2+ guidelines. This includes wearing a lab coat, long pants, closed toe shoes, nitrile gloves, facemask and faceshield. All work is to be hperformed in BSL2 certified lab spaces and as much of the work as is possible is to be carried out inside a biosafety cabinet. Confirm the reliability of RT-ddPCR results by running a 6-point standard curve in duplicate using the conditions, primers and probes described above. The concentration of the standard curve should range from 10 0 to 10 6 RNA copies/uL. To account to reverse transcriptase efficiency, the standard curve should be made from small RNA transcripts (704 -1363 nt) of the SARS-CoV-2 nucleocapsid (N) genes. These transcripts were kindly provided by the Grubaugh lab at Yale University (grubaughlab.com/). Store the data generated from these sampling on Clean Water Services computers and Oregon State University's server. The data on the OSU server is backed up nightly. Digitize the result from the laboratory analysis of collected samples and metadata generated/gathered for each sample into spreadsheets and store on Clean Water Services computers and OSU servers. Include the quality control data for each sample. For cases when any problem is encountered in the analysis, report the problem along with the corrective actions taken and changes to the standard operation procedures. Perform a quality assurance review on the data to ensure that all sample values were entered without error. This review consists of multiple manual checks to make sure that all laboratory data has been entered into the spreadsheet correctly.

The Ohio State University 

RNA/DNA was directly extracted from the viral concentrate using AllPrep PowerViral DNA/RNA Kit (Cat. No. 28000-50; QIAGEN, Germantown, MD, USA) following manufacturer's instruction. Briefly, 5μL of the DNA/RNA eluent extracted from the above step was applied to RT-qPCR following the manufacture instruction of the Prototype SARS-CoV-2 RT-qPCR detection kit for wastewater (Promega). For N1 and N2 gene quantification, RT-qPCR standard curves were generated by adding 5μL of the serial diluted (1:10) quantitative control dsDNA (2×10 3 -2×10 0 copies/μL) into the wells that contained the mastermix. Three technical RT-qPCR replicates were performed for the standard curves. The PCR cycling condition for the RT-qPCR included an initial reverse transcription at 45 °C for 15 min, reverse transcriptase inactivation/ GoTaq® activation at 95 °C for 2 min, followed by 40 cycles of denaturation at

This SOP applies to all research staff, hosted visitors and guests, volunteers, building staff, and service staff who enter the laboratory (MCE 2424). This manual will be reviewed annually by the Principal Investigator, Laboratory Supervisor and graduate students for changes or corrections to ensure that it is accurate. Review of this Manual is mandatory for all employees and staff working in the BSL-2 laboratory of Dr. Jennifer Weidhaas (MCE 2424) on SARS-CoV-2 containing wastewater samples. This Manual must be updated at least annually, and whenever there are changes in laboratory procedures that may change a worker's exposure. A copy of this Manual must remain in the lab, and must be accessible to lab personnel.

The individuals involved in this project are listed in the hour. Note that the coronavirus is likely inactivated, however, the sample will be handled by assuming the virus is still viable and other pathogens are also present. 4. All further procedures will occur in a BSC or a centrifuge with a biosafety cap a. After heat treating the sample. Place the bottle in the BSC. Add acid until the pH=3 b. Centrifuge the sample at 5000xg for 10 minutes. Retain the supernatant. Autoclave all glassware prior to use. c. Filter the sample through a 0.45 uM mixed cellulose water membrane filter. Autoclave the filtrate and then dispose of as hazardous waste. Record the volume of water filtered (typical volumes will vary from 80 to 200 mL depending in the influent characteristics) d. Place the filter in a falcon tube and store at -80 o C until further processing e. Extract the RNA via a commercially available extraction kit or the Griffiths manual extraction method (See below). Handle the filter and all extraction steps in a BSC until the final elution of the RNA in tris.

Label all tubes and filters with the chain of custody name and date for each sample 2.

Measure sample as per steps below and put into the Lysing Matrix E bead beater tubes (or equivalent) a. 10-200 ml of filtered sampled (0.45 uM filter), frozen at -80 o C, shattered (place the entire filter into the bead beater tube) SOP 3S.2H

3.

Add 0.5 ml CTAB mixture (10% wt/vol CTAB with 0.7 M NaCl with equal volume of 0.24 M potassium phosphate, pH=8.0) and 0.5 ml of phenol: chloroform:isoamyl alcohol (25:24:1) 4.

Vortex 10 minutes at setting 8 in horizontal position or use a bead beater system to homogenize 5.

Spin at 4 o C, 16 ,000 x g for 5 minutes 6.

Transfer the aqueous phase to a new, sterile 1.5 ml tube (take top layer, avoiding white cell debris layer) 7.

Remember the aqueous phase volume, then add the same vol of chloroform: isoamyl alcohol (24:1) to get rid of phenol 8.

Spin at 4 o C, 16,000 x g for 5 min 9.

Extract aqueous layer (take top layer, avoiding white cell debris layer) to a new 1. RT-qPCR data analysis:

1. Ensure there is no amplification in the negative control and the positive control Cts are as expected compared to the standard curve and the dilution used. If the positive control fails, rerun the analysis. If the negative control amplifies, use new primers, mastermix and PCR grade water and re-run the analysis. 2. Average all qPCR replicates on filter #2 and filter #3 3. If any triplicate qPCR has 1 of 3 or 2 of 3 ND, a. but the MHV-qPCR is positive flag the sample as present but below detection limits b. If the MHV-qPCR is negative, rerun the qPCR for the ND sample and include a replicate matrix spike sample c. If after re-analysis the qPCR still has any ND, flag the sample as present but below detection limits 4. Using the standard curve, estimate the gene copies per mL of wastewater based on the volume of water filtered, and the PCR dilution factor use to reach the target RNA concentrations 5. Keep a copy of the result in excel, on the Utah wastewater database and on the computer associated with the QS3. RT-qPCR data analysis: 1. Average all qPCR replicates on filter #2 and filter #3 2. If any triplicate qPCR has 1 of 3 or 2 of 3 ND, a. but the MHV-qPCR is positive flag the sample as present but below detection limits b. If the MHV-qPCR is negative, rerun the qPCR for the ND sample and include a replicate matrix spike sample c. If after re-analysis the qPCR still has any ND, flag the sample as present but below detection limits MHV-qPCR in singlet on filter #2

MHV-qPCR in singlet on filter #2 RT-qPCR data analysis: 1. Average all qPCR replicates on filter #2 2. If any triplicate qPCR has 1 of 3 or 2 of 3 ND, a. but the MHV-qPCR is positive flag the sample as present but below detection limits b. If the MHV-qPCR is negative, rerun the qPCR for the ND sample and include a replicate matrix spike sample c. If after re-analysis the qPCR still has any ND, flag the sample as present but below detection limits MHV-qPCR in singlet on filter #2 No need to have a full bottle, approx. 500ml is sufficient.

If manual composting is employed, the individual sample portions must be thoroughly mixed before pouring the individual aliquots into the composite container.

If wastewater sampler is not available, collect one grab raw sewage sample in the morning using a bucket from a sample site post grit chamber. • All the steps should be conducted in the Biosafety Level 2 cabinet except centrifugation and sample incubation.

• Negative Control: For every concentration process, include 1 negative control using 100ml of ultrapure water.

• Process control (to determine virus recovery) should be done for each new sampling site and sample type by spiking phi6 phages in the sample.

After initial determination of the recovery, it is recommended that process control to be included at least once a month. Generation) . 5 Components of the PCR mix for one reaction in the ddPCR assay: must be securely hooked on both ends of the holder; otherwise, pressure sufficient for droplet generation will not be achieved.

5.14. Open the QX200 droplet generator by pressing the button on the green top of the machine and place the cartridge holder into the instrument. When the holder is in the correct position, both the power (left light) and holder (middle light) indicator lights will be green.

Press the button on the top of the machine again to close the lid and begin the droplet generation process. The droplet indicator light (at right) flashes green after 10 sec to indicate droplet generation is in progress.

When droplet generation is complete, all three indicator lights will be solid green. Open the lid of the machine by pressing the button, and remove the holder (with the DG8 cartridge still in place) from the unit. Remove the gasket from the holder and discard it. The top wells now contain the droplets, while the middle and lower wells are nearly empty with a small amount of residual oil in them.

Make sure to keep the DG8 cartridge in the holder. • Slowly draw up 40 μl of droplets into the pipet tip (should take ~ 5 sec and ~5 μl of air is expected); do not aspirate >40 μl, as this causes air to percolate through the droplets • Pipet slowly. Apply a stable resistive force to the plunger to draw and aspirate droplets smoothly into and out of the pipet tips.

• To dispense droplets into the 96-well plate, position the pipet tip along the side of the well -near, but not at, the bottom of the well -and slowly dispense the droplets (~5 sec).

• Make sure to keep the plate covered while pipetting in order to prevent evaporation and contamination with particulates. 

Press the button on the green lid to open the droplet reader. Load the plate holder with your 96-well plate insider into the droplet reader and press the button on the lid again to close the cover. Make sure to confirm the three indicator lights are green before proceeding. SOP 4.3

In the QuantaSoft software, click the Setup button in the upper left of the screen in order to define your experiment and then click Run to start the ddPCR program. In an empty cell input the following formula (=STDEV()) and proceed to highlight all of the raw amplitude scores and then hit enter. This value will be your Standard Deviation and will be added to the highest droplet amplitude value in the NTC well you selected. This new amplitude value should then be applied to the rest of the samples in the run as a common Threshold value.

8.2.6. After this threshold has been set for all of the samples in your run you should then proceed to export the CSV file for the run so that it can be opened in Excel as well. 

The New York City Department of Environmental Protection provides, on a weekly basis, 1-liter 24-hr composite samples from the wet-well of all 14 wastewater treatment plants located in NYC. On arrival at our laboratory, 500 mL from each location is processed, and the remainder is frozen at -80℃. Detailed information on sample transport and safe handling and receiving is below in section III.F.

B. Pretreatment: Prior to processing, samples are rendered non-infectious by pasteurization at 60℃ for 60 min. Following this, the samples are centrifuged at 5,000 x g to pellet solids, then the supernatants are passed through a 0.22 filter using a disposable vacuum filter system (Corning 430769).

C. Quality Assurance: For quality control assurance, a matrix spike of a known titre of rotavirus RNA, a non-enveloped dsRNA virus to determine RNA recovery during RNA isolation from wastewater. In addition, samples may be spiked with a known titre of phi6, an enveloped dsRNA bacteriophage to test the effect of various processing methods on the recovery of infectious virions. Both spike-ins allow the determination of recovery rates of both viable and non-viable enveloped viruses. Inactivated and filtered samples are divided into six 40-mL parts to determine the effect of various processing methods (e.g., different concentration protocols, different means of storage). While establishing protocols, efforts are made to perform the experiment at least in triplicate within a sample if possible while testing the outcomes across multiple distinct samples. For qPCR experiments, all assays are performed in triplicate and include standards and template and enzyme free controls according to best practices (MIQE Guidelines). 500 mls of each wastewater sample is maintained at -80℃ as a recovery sample.

To determine the best method of virion concentration, virions in the filtrate are concentrated using one of four methods: PEG precipitation, AlCl 3 flocculation, skim milk flocculation, or ultracentrifugation. Dennehy Lab COVID SOP 1 1. PEG Precipitation Protocol a) 4 g PEG 8000 (100 g/L) and 0.9 g NaCl (22.5 g/L), are added to 40 mL filtrate. b) The filtrate is allowed to rest overnight at 4℃. c) After resting, the sample is centrifuged in a 50 mL Nalgene Polycarbonate Oak Ridge tube (Thermo Fisher Scientific 31380050) at 12,000 x g at 4℃ for 10 min. d) The supernatant is removed, pellet is resuspended in 1.5 mL TRIzol (Invitrogen 15596018) and transferred to a 2 mL centrifuge tube for RNA isolation.

Protocol a) 400uL of 0.3M AlCl 3 is added to 40 mL filtrate, then the pH is adjusted to 6.0 with 1M NaOH. b) The resulting mixture is incubated with agitation 100 rpm for 15 min at RT, then centrifuged at 3000 x g for 20 min at RT. c) The supernatant is removed, and the pellet is resuspended in 10 mL of 3% beef extract (Gibco Bacto DF0115173) at pH 7.4, incubated again with agitation (150 rpm for 10 min at RT), then centrifuged at 3000 x g for 20 min at RT. d) The pellet is resuspended in 1.5 mL TRIzol and transferred to a 2 mL centrifuge tube for RNA isolation.

3. Skim Milk Flocculation Protocol a) 1350 µl skimmed milk mixture (25g/L) is added to 40 mL filtrate. b) The pH is adjusted to between pH 3 to 4 with HCl 1N and NaOH. c) The sample is then incubated 2 hours at room temperature on a rocker set to ~ 400. d) To concentrate the virions, the sample is centrifuged 12,000 x g at 4℃ for 30 min. e) After removing the supernatant, the pellet is resuspended in 1.5 mL TRIzol and transferred to a 2 mL centrifuge tube for RNA isolation.

a) Filtrate is placed in a 5 mL thick walled polycarbonate centrifuge tube (Beckman Coulter 362305) and centrifuged at 200.000 x g at 4℃ for 60 min. b) The supernatant is removed and the pellet is resuspended in 1.5 mL TRIzol and transferred to a 2 mL centrifuge tube for RNA isolation.

To test the efficiency of the RNA extraction, Dennehy Lab COVID SOP 2 SOP 4S.1(H) some samples are spiked with rotavirus RNA of known concentration. a) Samples are processed in a dedicated RNA biosafety cabinet to minimize exposure to RNAses. All surfaces, such as bench tops, pipettes, and tip boxes, are cleaned with RNAse Zap and cross-contamination minimization strategies are employed (e.g. barrier tips). b) To extract RNA suspended in TRIzol, cold (4℃) chloroform is added in a 1:5 ratio, allowed to rest at RT for 5 min, then the sample is centrifuged at 12,000 x g at 4℃ for 15 min. c) The top aqueous phase is transferred to a fresh tube, and cold (-20℃) isopropanol is added in a 1:1 ratio. d) The resulting mixture is allowed to rest at RT for 15 min, and then centrifuged at 12,000 x g at 4℃ for 15 min to pellet the RNA. e) The supernatant is removed and the pellet was washed twice by adding 1 mL 75% ethanol, centrifuged at 12,000 x g at 4℃ for 3 minutes, then the ethanol is removed. f) After the second wash, the sample is air-dried for 10 min, then resuspended in 30µl RNA Protect. Samples are stored at -20℃.

a) The concentration and purity of RNA assessed using a QuBit 3 fluorometer (Thermo Fisher Scientific). b) A working solution is prepared and samples (1-20 ul) are diluted in up to 200 ul of working solution. c) Two standards (0 ng/ul and 10 ng/ul concentration) are used to generate a calibration curve on the Qubit before reading each sample. This process is repeated each time the Qubit is used for quality assurance. d) Before reading the samples, they are allowed to reach room temperature for 2 mins. e) The assay is highly selective for RNA over double-stranded DNA (dsDNA) and is accurate for initial sample concentrations from 250 pg/µL to 100 ng/µL. 7. Quantitative PCR: Primers and probes a) Samples are tested for the presence of SARS-CoV-2 RNA using the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel (IDT Inc.) and according to the instructions provided by the CDC. b) Each RT qPCR assay is performed with two no-template controls, and a ten-fold serial dilution of standards (nCoVPC positive control) across five orders of magnitude. Each sample is assayed in triplicate with N1 or N2 primers/probes. c) Reverse transcription is performed using the Thermofisher Dennehy Lab COVID SOP 3

TaqPath 1-Step RT-qPCR Master Mix and the ABI StepOne instrument. d) ROX reference dye is used to normalize the fluorescent reporter signal. e) Thermal cycling is performed using the conditions established for the TaqPath 1-Step RT-qPCR amplification. f) Reaction efficiency is assessed using plots of standard Cts plotted against standard concentration. Each ten-fold standard dilution should be dilution should be ~3.3 cycles apart. g) A sample is considered negative if all 2019-nCoV marker (N1, N2) cycle threshold growth curves DO NOT cross the threshold line within 40.00 cycles (< 40.00 Ct). A sample is considered positive for 2019-nCoV if all 2019-nCoV marker (N1, N2) cycle threshold growth curves cross the threshold line within 40.00 cycles (< 40.00 Ct).

The Lab will follow the guidelines posted by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health. These guidelines describe acceptable biosafety practices in biomedical and microbiological laboratories and can be found at: http://www.cdc.gov/OD/ohs/biosfty/bmbl5/bmbl5toc.htm. D343 is a research laboratory and classified as BSL2. All work conducted in the BSL2 lab must adhere to BSL2 guidelines and regulations. All biohazardous waste generated in D343 is classified as BSL2 biohazardous waste.

a. Include the PCR Positive Control (5 μL PC), PCR Negative Control (5 μL PCR Grade Water), Extraction Positive Control (5 μL), and Extraction Negative Control (5 μL) for each test run. b. Include 5 L of each dilution of reference material that will be used to produce a standard curve for quantification (see below). 5. Cover the plate and briefly spin the plate, if necessary, to settle contents and remove air bubbles. 6. Perform real-time PCR with settings and cycling program below. Ensure the instrument is set to record fluorescence following the 60°C amplification step.

PCR control reactions:

The following control reactions will be performed in parallel with each set of wastewater samples that are extracted and tested in RT-PCR.

• PCR Positive Control (PC): A positive template control is needed to confirm the PCR plate is valid. The positive control will be included on each PCR run and should test positive for the SARS CoV-2 target. To perform the PCR positive control, 5 ul of a linear DNA containing SARS-CoV-2 N1 target region will be added to a RT-PCR reaction. This material is provided in the Water SARS-CoV-2 RT-PCR Test kit.

• PCR Negative Control (PCR Grade Water): A "no template" (negative) control is needed to confirm the PCR plate is valid. PCR Grade water is used and will be included for each PCR run. The negative control should test negative for the SARS CoV-2 target. To perform the PCR negative control, 5 ul of a PCR Grade Water will be added to a RT-PCR reaction. This material is provided in the Water SARS-CoV-2 RT-PCR Test kit.

• Extraction Positive Control: 5 ul of the Extraction Positive Control sample (see "Extraction control samples" above) is added to a RT-PCR reaction.

• Extraction Negative Control: 5 ul of the Extraction Negative Control sample (see "Extraction control samples" above) is added to a RT-PCR reaction.

• A standard curve for quantification of SARS-CoV-2 and OC43 will be prepared using at least three (3) ten-fold dilutions of the respective target reference material in nuclease-free water. • Each standard curve will be analyzed by RT-PCR at the same time as the unknown samples to be quantified.

• The quality of the standard curve will be assessed by plotting the results as a linear regression of Ct versus the log of the RNA quantity and evaluating the slope and coefficient of correlation (R 2 ).

• All test controls will be examined prior to interpretation of results. If the controls are not valid, the results cannot be interpreted. See "Quality Assurance Plan" section below .

• To obtain the most appropriate Ct values, analysis for SARS CoV-2 target will be performed by manually setting the fluorescence threshold. The threshold will be adjusted to the inflection point for the exponential phase of the curve and above background signal. This will be done while viewing all amplification curves for a given run, on a logarithmic scale. The same procedure will be used for analysis of each PCR run.

Each RT-PCR run requires the following specific validity criteria to be met for the results to be considered valid.

• Expected results for the (1) PCR positive control, (2) PCR negative control, (3) Extraction positive control, and (4) Extraction negative control shown in the table above must be obtained for each PCR run in order for the run to be deemed valid. If the plate controls are not valid, the results are not valid, and the testing must be repeated.

• Dilutions used must encompass the range of Ct results to be analyzed and for which quantitative data will be reported.

• The quality of each standard curve must display acceptable slope and coefficient of correlation (R 2 ).

• Each sample is considered valid when analyzed on a plate demonstrating the expected control results as described in the table above. The workflow begins with fortification of the internal standards (spike), non-infectious retroviral VLPs (which have the same size and properties as SARS-COV-2) that contain an RNA genome with an engineered sequence, followed by the extraction of the nucleic acid from the wastewater samples collected from the facilities. Nucleic acids are isolated, concentrated and precipitated by polyethylene glycol (PEG) and the RNA will be purified from the extracts using the QIAGEN QIAamp Viral RNA Mini Kit. The purified RNA is reverse transcribed into cDNA and amplified using the ThermoFisher TaqPath™ RT-qPCR Master Mix and Applied Biosystems™ 7500 Fast Real-Time PCR Instrument.

In the process, the probes anneal to the specific SARS-CoV-2 target sequences located between unique forward and reverse primers for the following genes:

• N1 (N protein)

• N2 (N protein)

• Puro (internal standard)

During the extension phase of the PCR cycle, the 5' nuclease activity of Taq polymerase degrades the probe, causing the reporter dye to separate from the quencher dye, generating a fluorescent signal. With each cycle, additional reporter dye molecules are cleaved from their respective probes, increasing the fluorescence intensity. Fluorescence intensity is monitored at each PCR cycle by the real-time PCR instrument.

The data are analyzed, then interpreted by the Applied Biosystems™ Software. 13) Pipette 5 μL of nuclease-free water into the NTC sample wells (Figure 1 ). Securely cap NTC wells before proceeding. 14) Cover the entire reaction plate and move the reaction plate to the specimen nucleic acid handling area. 15 ) Pipette 5 μL of the RNA extract from each sample into each well. 16 ) Seal the plate with MicroAmp™ Optical Adhesive Film, vortex the plate for 10 seconds to ensure proper mixing, then centrifuge for 1 minute at 2000 rpm to collect the liquid at the bottom of the reaction plate. A-N1 S1-N1A S2-N1A  S3-N1A  S4-N1A  S5-N1A  S6-N1A  S7-N1A S8-N1A  S9-N1A  S10-N1A  S11-N1A  S12-N1   B-N1  S1-N1B  S2-N1B  S3-N1B  S4-N1B  S5-N1B  S6-N1B  S7-N1B  S8-N1B S9-N1B S10-N1B S11-N1B S12-N1 C-N2 S1-N2A S2-N2A S3-N2A S4-N2A S5-N2A S6-N2A S7-N2A S8-N2A S9-N2A S10-N2A S11-N2A S12-N2 D-N2 S1-N2B S2-N2B S3-N2B S4-N2B S5-N2B S6-N2B S7-N2B S8-N2B S9-N2B S10-N2B S11-N2B S12-N2 E-Puro S1-Puro S2-Puro S3-Puro S4-Puro S5-Puro S6-Puro S7-Puro S8-Puro S9-Puro S10-Puro S11-Puro S12-Pur A maintained instrument will be calibrated for many dyes. In addition to those dyes, the instrument operator must calibrate the instrument for ABY™ dye and JUN™ dye that are used with this kit. For all other assays, refer to the standard calibration process.

This procedure is specific for the 7500 Fast Real-Time PCR Instrument using SDS Software v1.5.1. For more information, see the documents listed in "Related documentation" on page 73. 5. Confirm the labeling of the control wells.

• The template included positive control and one negative control assigned to wells for reference.

• Move the control well assignments by copying the existing control wells and pasting them according to their location on the physical plate.

Quality control requirements must be performed to monitor reagent, extraction and assay performance. Duplicate samples and standards should be included for each RT-qPCR analysis.

All positive controls will be tested prior to running diagnostic samples with each new kit lot to ensure all reagents and kit components are working properly. Both negative control (NTC), and the appropriate positive control (nCoVPC) should be included in each amplification and detection run. The internal control was generated using non-infectious retroviral VLPs (which have the same size and properties as SARS-COV-2) that contain an RNA genome with an engineered sequence. The internal control engineered virus with Puro gene will be fortified into the wastewater sample to control for assay quality and extraction efficiency. Five points (with duplicates) calibration equations will be developed for quantification the copy numbers of the SARS-CoV-2 in wastewater samples. The efficiency of RT-qPCR will be calculated from the slope of a standard curve (S) using the recommended value -3.3 +/-10% with coefficients > 0.95. A low efficiency indicates that primers and/or probes are performing poorly. No single efficiency (as a percentage) has been set as a limit for data to be acceptable, although 90% or greater is an accepted norm. The recovery of the internal standard should be greater than 10%, which conformed to ISO15216-2:2017 standards (>1%).

Since there are no synthetic SARS-COV-2 RNA available at this moment, the spiked internal standard non-infectious retroviral VLPs genome with an engineered RNA sequence was used as the positive controls to assess the PCR inhibitory effects.

The LOD study established the lowest SARS-CoV-2 viral concentration (Genomic Copy Equivalents or GCE) that can be detected by the method in a particular specimen type at least 95% of the time.

Each waste water sample was spiked with purified RNA with 4.6 x 10^6 copies of Puro [internal standards (spike), non-infectious retroviral VLPs which have the same size and properties as SARS-COV-2) that contain an RNA genome with an engineered Puro sequence].

The recovery rate of each sample was determined by: 

All steps completed in the workstation designated for REACTION MIX PREP.

• FULL DECONTAMINATION of workstation designated for REACTION MIX PREP. Be sure to decontaminate tube racks and the lid of a 96-well PCR tube rack (part of Cat.

No. 50-550-279) for this step. • Gloves should be changed frequently, including after decontamination.

The number of samples can be changed in this spreadsheet to update required volumes for reaction mix components. For a full plate, with 6 standards, one duplicate and one NTC, set the number of samples = 24 (96 reactions). This sheet will also indicate whether to use a 1.5 mL or 2 mL tube for the reaction mix. For 12 samples, use a 1.5 mL tube.

• If running an N1 plate, remove an N1 primer/probe 107 µL aliquot from the -20°C freezer and thaw on ice. Alternatively, if running an N2 plate, instead remove an N2 primer/probe 107 µL aliquot from the -20°C freezer and thaw on ice. • Obtain the TaqPath TM 1-Step RT-qPCR Master Mix (4x), from the refrigerator. Keep on ice. • Mix the TaqPath TM 1-Step RT-qPCR Master Mix (4x), N1 or N2 primer/probe by inversion 5 times and return to ice. • Centrifuge the primer/probe for 5 sec in a mini microcentrifuge then place on ice.

• Obtain a 1.5 mL or 2.0 mL tube. Label the tube "N1 Reaction Mix" or "N2 Reaction Mix" depending on the target being run. Place the labeled tube in a previously decontaminated tube rack. • For a stock of reaction mixture master mix, use the table below. N = number of samples (note: if N < 15, add N + 2 amount of volume for each step). 

Carefully transfer the covered plate to the previously decontaminated workstation designated for TEMPLATE PREP.

• Use a previously decontaminated P10 pipette to transfer nuclease-free water and standards (volumes indicated below) into the appropriate wells. While adding, pipette up and down three times to mix the template with the reaction mix in the well. Change tips after each addition. ○ No template control ■ Add 5 µL of nuclease-free water into wells designated for no template control (NTC). ○ Samples ■ Briefly vortex and spin down each sample and store on ice. ■ Add 5 µL of each sample RNA into the designated wells. ○ Standards ■ Change gloves and retrieve standards from storage (ice or 4°C). ■ Add 5 µL of each standard into designated wells.

Tip tip! Model the pipette tip box after the 96 well plate and keep track of loaded wells based on empty spots in the tip box.

• Seal the reaction plate with optical adhesive film using the adhesive seal applicator (video instructions). • Centrifuge the plate briefly (<1500 rpm, 1 min, 4°C, based on recommendation for

StepOnePlus calibration plates) to bring the contents to the bottom of the well and 

• Retrieve the plate from the centrifuge and load into the real-time PCR instrument, orienting the wells in the correct direction. • Check that the saved run has all the correct conditions and that the plate set-up is correct and saved. RT-qPCR run information and plate set-up should be entered and saved in the software before starting step 3.4 to ensure that the RT-qPCR can begin as soon as the plate has been prepared. Ideally, a template can be used to expedite this process. References for the StepOnePlus can be found in Appendix B.

StepOnePlus Run Set-up To operate the StepOnePlus instrument and software, refer to the instructions on Pages A-1 to A-2 of EPA Method 1696. Please note that the conditions required for the SARS-CoV-2 qPCR SOP are different from those in EPA Method 1696. Differences are summarized below, with reference to the steps defined in EPA Method 1696: Ensure that the StepOnePlus is set up as shown below, and that ROX signal will be appropriately collected:

SOP 4S.5H

Let the wastewater sample thaw overnight from -20°C storage

Spike the sample with the Process Control (Hs_RPP30 or OC43)

Filter the sample through 0.45 µm nongridded sterile cellulose membrane filter (Sartorius TM )

Prerinse a Corning TM Spin-XTM concentrator (100 kDa molecular weight cut-off) with deionized water as described in the manufacturer's manual

Fill the prerinsed concentrator with 20 mL of the filtrate. Ensure screw closure is fully seated. Insert assembled concentrator into a swing bucket centrifuge that can accommodate 50 mL conical bottom tubes. Centrifuge at 3,000 g for 30 min

Repeat the steps 4-5 until the pocket of the concentrator (for concentrated sample) reached approximately 1 mL. Record the volume of filtrate used

RNA Extraction: 1. Extract RNA from concentrated samples with the RNeasy Mini Kit (Qiagen) with 40 µL elution volume following the manufacturer's protocol

RT-qPCR): 1. Use two primer pairs (N1 and N2) and probes from 2019-nCoV CDC EUA Kit

Follow CDC guidelines for reagent and controls preparation

Use 20 µL as the reaction volume, which includes 10 µL iTaq universal probes one-step reaction mix, 0.5 µL iScript advanced reverse transcriptase, 1.5 µL of primer and probe mix, 3 µL of water

Use nuclease-free water as negative template control (NTC )

Use 2019-nCoV_N_Positive Control as the positive control

Follow the following protocol for amplification: 50°C for 10 min, 95°C for 1 min followed by 40 cycles of 95°C for 10 sec, and 60°C for 30 sec

Complete medical self-assessment

Enter the ECSL 1B11 labs

Clean all tables, hoods, and ovens

Prep the reception log for the sample arrival

Exit the laboratory and receive the coolers on arrival from the field sites; record the reception and mark the weight of the as received coolers

Weigh and record the weight of the recovered coolers

When all stations have submitted samples, open the coolers, remove the sample vessels from all lines, and immediately spike in a 1/100 by volume 10% Tween-20 surfactant solution. The final concentration of Tween-20 will be 0.1%. This enables better concentration and also the inactivation of the virus

Spike an internal control. The internal control used for this sampling campaign is an inactivated Bovine Coronavirus utilized in immunization of cows

Disinfect all components by spraying 70% ethanol; after allowing the ethanol to evaporate for 10 minutes, wipe the interior and exterior of the cooler and the exterior of the cold packs with a dilute bleach solution

Soak the tubing lines in a 70% ethanol solution for 10 minutes

the ice packs to the fridge to freeze for the next day's sampling. Students will, in order, perform the following tasks after Tween-20 spike: 17. The graduate researcher will remove the volume required for the concentration step (likely 50-mL of media)

Measure the post-Tween-20 pH

Setup the vacuum system for the total suspended solids (TSS) measurement

Remove blank and dessicated filters, measure the weight

Filter the sample through the TSS apparatus

Place samples in the oven for drying overnight

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

2019-Novel coronavirus (2019-nCoV) real-time rRT-PCR panel primers and probes

For wells with a positive control, confirm that Task is set to Standard

For wells with a negative control, confirm that Task is set to NTC

Edit the plate layout to assign a unique sample name to each well with a patient sample in the physical plate

For wells with a wastewater sample, confirm that Task is set to Unknown for all detectors

Under Settings (Figure 12), bottom left-hand box, change volume to 20 µL

Guidelines for PCR techniques Master mix -premixed solution of most of the required components for RT-qPCR. The purchased master mix for this protocol TaqPath™ 1-Step RT-qPCR Master Mix (4x Concentration) -contains thermostable MMLV reverse transcriptase, dNTPs, UNG, ROX™ dye, and thermostable Fast DNA polymerase, facilitating easy reaction set up

Multiplex -when multiple genes (targets), each with their own unique probe, are detected in the same reaction (tube/well). This protocol does not currently use multiplexing

circular DNA molecule; in this protocol, the 2019-nCoV_N_Positive Control (used as a positive control and for standard curves for the N1 and N2 targets) is a plasmid that contains the complete nucleocapsid gene from

DNA) designed to attach (anneal) to two regions flanking the target region to be amplified. Once annealed, primers allow DNA polymerase to begin replication from either end of the target region (during the elongation or extension step). Both a forward (f) and reverse (r) primer are needed. Because this protocol looks to amplify two target regions (N1 and N2), two sets of f and r primers are required. Another set of primers

Probe -labelled strands of short DNA (oligonucleotides) that bind to a spot on the target region that give off a fluorescent signal during the reaction, allowing for detection and quantification. Probes for the N1 and N2 assay: 5' FAM / 3' Black Hole Quencher® (BHQ). Probes for the BCoV control assay: 5' FAM/ZEN/ 3' IBFQ (Iowa Black FQ)

quantitative polymerase chain reaction (qPCR) -often used interchangeably with "real-time polymerase chain reaction". qPCR allows for quantification of the target nucleic acid sequence

Real-time" indicates that measurements are made in real-time

Each target (N1 and N2) will require its own separate reaction mix, since the primers/probe for N1 are different from the primers/probe for N2 and this protocol does not currently use multiplexing. Similarly, for the BCoV control assay, the BCoV target will require its own separate reaction mix with its own primers/probe. Reverse transcription (RT) -the process which generates complementary DNA (cDNA) from RNA

Storage Conditions" column. For those reagents for which aliquots are required, prepare and store as follows, after a FULL DECONTAMINATION (Section 1.5) of the REACTION MIX PREP, TEMPLATE PREP, or Biological Safety Cabinet workstations. Gloves should be changed frequently, including after decontamination. • 2019-nCoV RUO Kit containing 3 sets (N1, N2, and RP targets) of premixed primers and probes (Cat. No. 10006713; 750 µL) In the previously decontaminated workstation designated for REACTION MIX PREP: ○ Mix the N1 target primer/probe mix by inversion 5 times

Aliquot the N1 target primer/probe mix in 1.5 mL LoBind tubes: ■ Using a P200 pipette, divide into 7 separate 107 µL aliquots and label "N1 primer/probe 107 µL" with the date and initials. • These aliquots contain enough primer/probe mix for a plate containing 13 samples, a NTC

○ FULL DECONTAMINATION of the workstation designated for REACTION MIX PREP Change gloves and repeat the above process for the N2 target. ○ Mix the N2 target primer/probe mix by inversion 5 times. ○ Centrifuge the N2 target primer/probe mix for 5 sec in a mini microcentrifuge then place on ice

Aliquot the N2 target primer/probe mix in 1.5 mL LoBind tubes: ■ Using a P200 pipette, divide into 7 separate 107 µL aliquots and label "N2 primer/probe 107 µL" with the date and initials. • These aliquots contain enough primer/probe mix for a plate containing 13 samples, a NTC

○ The mix for the RP target will not be used in this protocol. RP can be labeled with the date and initials and stored as delivered at -20°C

FULL DECONTAMINATION of the workstation designated for REACTION MIX PREP. soon as the plate has been prepared. Ideally, a template can be used to expedite this process (See Appendix B for information and resources for the StepOnePlus instrument and software)

curve will be required for each target/plate (N1 or N2), though the same standard is used for both

All steps are performed in the workstation designated for TEMPLATE PREP

• Gloves should be changed frequently, including after decontamination

Strike through the label which reads "original stock" and label tube with "STD 1" with a lab pen or marker. ○ Record the date indicated on this aliquot. Enter this date in the appropriate cell of the "N1/N2 Standard Curve" tab of the accompanying spreadsheet

• Obtain a decontaminated microcentrifuge tube rack and five (5) 1.5 mL LoBind tubes and label the tubes "STD 2" -"STD 6

Pipette 18 uL of nuclease-free water (using a P100 or P200 pipette) into each of the tubes, starting with STD 6

Pipette 18 µL of nuclease-free water into the STD1 tube containing 8 µL of positive control plasmid. Vortex using a vortex mixer, spin down briefly with a mini microcentrifuge

Using a P10 pipette, transfer 2 µL of STD 1 to the STD 2 tube containing 18 µL of water, to make a 1 in 10 dilution. Vortex, spin down briefly

transfer 2 µL of STD 2 to the STD 3 tube containing 18 µL of water, to make a 1 in 10 dilution. Vortex, spin down briefly, and place in the tube rack. Perform a serial dilution by repeating this procedure according to Table 3.4.1 to make all 6 standards. Be sure to use a new tip for each transfer and immediately vortex and spin down each new standard after it is made

?url=https%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FLSG%2Fmanuals%2FTaqPath_qPCR_MasterMixCG_man.pdf&title=VGFxUGF0aC Z0cmFkZTsgcVBDUiBNYXN0ZXIgTWl4LCBDRw== (TaqPath 1-Step) TaqPathTM 1-Step RT-qPCR Master Mix

Set up extraction efficient control samples by seeding sample with various concentrations of heat-inactivated SARS-Related Coronavirus 2

glycine, 3% beef extract

up RNA extraction efficiency control/positive control using heat-inactivated SARS-Related Coronavirus 2

Perform RNA extraction using QIAamp Viral RNA Kit

Quantify RNA using nano-drop

USA) following the manufacturer's protocol 17. Proceed directly with PCR and ddPCR or store at -20 °C until analysis 18. Perform ddPCR using N1, N2 primers and probes reported by CDC 19. Prepare ddPCR reaction following the instruction from Bio-Rad

Analyze the ddPCR data using QuantaSoft Analysis Pro software v

Thermo Electron Corporation) 3. Microcentrifuge 4. Tube rotator or stir plate 5. Scale 6. Thermal PCR cycler (ABI 2720 Thermal Cycler

Pipette aliquot of bovine coronavirus (BCoV) stock into the sample to target 1000-fold dilution and then close bottles and rock gently for 10 minutes to mix a. Centricon: 150-µL spike into 150-mL sample aliquot b. PEG: 40-µL spike into 40-mL aliquot or 200-µL spike into 200-mL aliquot

Centrifuge samples at 4,000 rpm (~3,200×g) for 30 minutes at 4°C to pellet solids. a. Use supernatant for subsequent sample processing with Centricon or PEG b. Discard pellet or archive for separate analysis Sample concentration with Centricon Plus-70 Centrifugal Filter Devices

Pre-rinse Centricon filter to remove glycine residue: a. Fill the sample filter cup with up to 70 mL of DI or Nanopure water b. Close the cup with lid provided c. Centrifuge at 4,000 rpm (~3,200×g) for 5 min at room temperature d. Discard the filtrate and perform a recovery spin as follows: i. Turn the concentrate cup upside down and place on top of the sample filter cup ii

Concentrate sample with pre-rinsed Centricon filter: a. Fill the sample filter cup with the contents from one 50-mL conical tube b. Close the cup with lid provided c. Centrifuge at 4,000 rpm (~3,200×g) for 30 min at 10°C d. Remove the device from the centrifuge, record filtrate volume, and discard filtrate e

The CDC currently recommends that routine viral testing of specimens, such as the proposed activities, can be handled in a BSL-2 laboratory using Standard Precautions ( https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html ). While the ability for COVID-19 to be transmitted via wastewater has not been documented, we will assume samples contain infectious viral particles as well as potentially hazardous bacteria. To date, no study has shown that SARS-CoV-2 in human feces is infectious. Moreover, current thinking is that given the dilute nature of wastewater and the presence of inactivating substances (e.g. detergents, solvents) will render any wastewater-borne SARS-CoV-2 non-infectious. Despite being a significant concern, no studies have reported being able to isolate viable virus from wastewater. Current CDC recommendations do not stipulate that personnel take any extra precautions beyond standard practices when handling wastewater ( https://www.cdc.gov/coronavirus/2019-ncov/php/water.html and https://www.who.int/publications-detail/water-sanitation-hygiene-and-waste-management-for-co vid-19 ).

Regulations A. Access, Training and Responsibilities 1. Access is limited to individuals involved directly in growth media prep, Dennehy Lab COVID SOP 4 SOP 4S.1(H) clean up, lab prep, and research. One technician will work at a time in D343 with duties being rotated among three trained individuals. 2. Beth Lamanna, Director of Public Safety, will be alerted as to who will be working each day 24hrs in advance. 3. The individuals listed below will work on this project; before engaging in this work, they must be trained in the safe manipulation of recombinant DNA molecules and the organisms that contain them and/or infectious agents and such training must be documented: 4 . Access for other individuals is with permission of lab staff:• Construction/Maintenance: Any construction/maintenance work requires advanced 24hr notice to the lab staff. • Cleaning: Only as requested by Lab staff through the work order system. • Emergency: Entry permitted in conjunction with notification of Lab staff by text and email (cell phones numbers on are on the doors) 5. The lab doors will be closed when a BSL2 agent is in use. 6 . All staff and students are required to read, understand, and follow these regulations before working in D343. 7. All staff and students working in D343 will receive training from their instructor concerning use of the equipment. 8. John Dennehy will train permanent and part-time college laboratory technical staff on aseptic techniques appropriate for handling pathogenic agents. This will include the potential hazards associated with the work involved, the necessary precautions to prevent exposures, and the exposure evaluation procedures. Records of training are maintained in the Dennehy Laboratory. 9. Personnel will receive annual updates or additional training as necessary for procedural or policy changes. 10 . Personnel are advised of special hazards and are required to read and follow instructions on practices and procedures. 11. Any staff or students found in violation of the regulations may have their access to room D343 and other laboratory spaces terminated. 12. The Chair of the Department of Biology is responsible for seeing that the consequences of student or staff actions are rectified, including correction of damages and violations.Dennehy Lab COVID SOP 5 SOP 4S.1(H) B. Apparel 1. Gloves and N95 masks will be provided to all personnel for use in transit to the laboratory. 2. Once at the lab, these items will be removed and a different set will be provided for use in the laboratory. New PPE will be provided for all employees after they are finished working for their travel home. 3. Requisite PPE, including coat, gloves, safety goggles, and N95 masks, will be provided to all personnel, who will be required to wear them at all times in the laboratory. 4. All PPE is single use and will be autoclaved prior to disposal.a) The use of N95 masks requires that workers be enrolled in a respirator program that is run by the Environmental Health and Safety Office. We will coordinate with Parmanand Panday or William Graffeo to ensure this is completed. b) Personnel will be medically cleared by a physician whose written certification is sent to the EHS Office by June 1 st or as soon as possible. 5. Personnel entering room D343 will be required to wear closed-toe shoes and have long hair tied back. 6. Personnel working in D343 at BSL2 must wear lab coats at all times, lab coats are assigned to an individual. This protective clothing is removed and left in the laboratory before leaving for non-laboratory areas (e.g., restroom, cafeteria, library, or administrative offices). All protective clothing is either autoclaved or laundered at least once a semester. 7. Gloves are worn when handling microorganisms or hazardous chemicals.Gloves are disposed of when contaminated, and removed when work with infectious materials is completed or when the integrity of the glove is compromised. Gloves are placed in a biohazard bag and autoclaved prior to disposal. Disposable gloves are not washed, reused, or used for touching "clean" surfaces (keyboards, telephones, etc.), and they should not be worn outside the lab. Hands are washed with soap and water following removal of gloves. 8. In a BSL2 lab, safety goggles or safety glasses are worn for normal lab procedures involving liquid cultures that do not generate a splash hazard (e.g., proper pipetting, spread plates, etc.). Safety goggles and visors or safety goggles and masks are worn when performing procedures that may create a splash hazard. 9. When working in a biosafety cabinet, only lab coats and gloves are needed for personal protection. cosmetics are not permitted in the lab. Food for human consumption is never stored in the lab.

A red biohazard sign must be posted on the entrance to the laboratory when etiologic agents are in use. Information to be posted includes the agent(s) in use, biohazard symbol, biosafety level 2, the investigator's name and telephone number, any personal protective equipment that must be worn in the laboratory, and any procedures required for exiting the laboratory. 3. Persons wash their hands upon entering the lab, after they finish working in the lab, after removing gloves, and before leaving the laboratory. 4. Work surfaces are decontaminated prior to beginning any work in these rooms, on completion of work or at the end of the day with 10% bleach solution. Any small spill or splash of viable material should be decontaminated with an equal volume of 20% bleach solution (Using an equal volume of 20% bleach makes the final concentration 10%). a) All procedures are performed carefully to minimize the creation of splashes or aerosols. Any procedure that would potentially create aerosols will be performed within the biosafety cabinet. Centrifuges in the BSL2 laboratory must have sealed rotors.(1) Centrifugation -All centrifugation in the BSL2 lab use Thermo Scientific™ Sorvall™ Legend™ Micro 21 centrifuges that have a click seal bio lid. (2) Homogenization -This can be performed using a special adaptor on the vortex that allows tubes to be shaken at high speeds that contain cells or tissues and shearing beads. This action is performed in the BSC to avoid potential spills and/or aerosols. Alternatively, a bead beater is used. The unit in the lab is the FastPrep-24 which has a lid that maintains a tight seal during homogenization preventing aerosols. Following both procedures, the organisms are killed and the cellular contents are released. A kit is used to isolate the DNA, RNA or proteins. (3) Vortexing -When using the vortex to resuspend cells or break-up pellets, this procedure is carried out in the BSC to prevent spills or aerosols. 5. Mouth pipetting is prohibited; mechanical pipetting devices are used. 6. A limited number of needles and syringes are used for reconstituting reagents. After use, these materials are placed in a puncture-proof red sharps container placed near the area of work. Do not recap needles. at increased risk of acquiring infection -e.g., those who are immunocompromised or immunosuppressed -or for whom infection may have serious consequences, should consult with their physician to determine the appropriate level of participation in the lab. 2. If two individuals are working the same day, a one-hour gap between their hours will be imposed to allow any potential airborne virus to settle (we will minimize occasions where multiple people work per day).

E. Transfer and receipt of materials 1. On Fridays, Dr. Dennehy will take delivery of wastewater samples and bring them to QC, likely in the afternoon. 2. On Fridays, 14 liters of wastewater (in 500 mL bottles) will be picked up from Newtown Creek Wastewater Treatment Plant on Fridays. Samples are prepared by DEP personnel in sealed 500 mL bottles that have been double-bagged to prevent leakage. 3. Collection personnel will wear a respirator, face shield, lab coat and gloves when receiving the samples from the DEP. 4. The samples will be placed in a large cooler and transported to the Dennehy Lab at QC. The inside and outside of the cooler will be wiped down with bleach or hydrogen peroxide solution following use. 5. Upon arrival, bottles will be wiped down with a bleach solution in a Class 2/A2 biosafety cabinet. SARS-CoV-2, if present in sample, will be rendered non-infectious by heating bottles to 60°C for 60 min. The temperature treatment is intended to inactivate viruses and pathogens, but not disrupt viral genomes. 6. Cultures, tissues, or potentially infectious wastes are placed in a container that prevents leakage during collection, handling, processing, storage, and transport. 7. For each sample site, 500 ml is processed as above and a second 500 ml maintained in the -80°C as a backup.F. Disposal of Materials and Decontamination 1. All cultures, swabs, tips, plates and waste containers are decontaminated by autoclaving prior to disposal by incineration. Liquid bacterial cultures are inactivated by adding an equal volume of 20% bleach prior to autoclaving (Using 20% bleach will ensure that a final concentration of 10% has been achieved). Red-bag materials to be decontaminated outside of the immediate laboratory should be placed in a durable, leakproof container for transport from the laboratory. All red-bag waste generated in the Dennehy lab is BSL2 biohazardous waste. 2. Laboratory equipment and work surfaces should be decontaminated with 5% Hydrogen Peroxide or 10% bleach on a routine basis and after work with infectious materials is finished.The biosafety cabinet should be wiped down with a 5% Hydrogen Peroxide or 10% bleach solution before and after use. 4. Following any procedures, the cabinet will be sterilized using its UV lamp.G. Spills 1. Overt spills, splashes, or other contamination by infectious materials should be decontaminated with an equal volume of 20% bleach (Using an equal volume of 20% bleach will ensure a final concentration of 10%). An overt spill is defined as the following: a) Spills greater than 5 mL (BSL-2, toxic chemicals) outside primary containment b) Spills that may contain broken glass or other sharps c) Spills that result in an exposure d) Spills that present an inhalation hazard e) Spills that cannot be easily cleaned f) Spills that endanger people or the environment 2. In the event of an overt spill, EHS, Dr. Dennehy, and Fire/Safety Director should be informed and a lab incident form should be filed (cell phones on doors). Appropriate PPE should be used when cleaning. All cleanup material should be disposed of as biohazardous waste. 3. For spills outside the biosafety cabinet, the spill should be decontaminated by covering with paper towels and soaking in an equal volume of freshly made 20% bleach solution or disinfectant for at least 30 minutes. The area at least 2 feet around the spill should also be cleaned with 10% bleach or disinfectant (Including furniture/walls). Spills that contain broken glass or sharps should also be treated with bleach but the material should be picked up using a dustpan and brush. 4. For spills inside the Biosafety Cabinet, the spill should be covered in paper towels and the paper towels soaked in an equal volume of freshly made 20% bleach solution or 70% alcohol for at least 30 minutes. The work surfaces and equipment in the BSC should be wiped down with disinfectant while the spill is soaking. All cleanup material should be disposed of in the biohazardous waste container. 5. For spills inside equipment like the centrifuges or incubators, turn off the equipment and leave the door closed for at least 30 minutes to reduce aerosol exposure before cleaning up the spill. Treat the spill as in step 3 and 4. 6. For spills inside equipment like the centrifuges or incubators, which involve glass or a breakage, turn off the equipment and leave the door closed for at least 30 minutes to reduce aerosol exposure before cleaning up the spill. Treat the spill as in step 3 and 4 with the addition that glass should be removed post decontamination, with a forceps and transferred Dennehy Lab COVID SOP 9 SOP 4S. 1(H) to the glass biohazardous waste container using a designated dust-pan and broom. 7. A sign should be taped on the equipment, indicating a spill occurred until the decontamination period has passed. 8. In the event of a chemical spill, clean it up immediately after consulting the SDS and contacting EHS and the Fire/Safety Director. 9. Spills and accidents that result in overt exposures to infectious materials are immediately reported to Dr. Dennehy, and to EH&S. Medical evaluation, surveillance, and treatment are provided as appropriate and written records are maintained. 10. Broken glassware that is not contaminated with biohazardous materials should be swept up with the D343 designated broom and dustpan and discarded in the glass disposal box. 11. Broken glassware that contains live cultures or other biohazardous material should be saturated with an equal volume of 20% bleach solution. After 15 minutes, the debris should be "swept" up into an autoclave bin using a plastic beaker and/or paper towels. After being autoclaved, the glassware can go into the glass disposal box and the paper towels can go into the regular trash. 

The following procedure was used in August of 2020 by IDEXX Laboratories for WRF Study 5089. Protocols for using the IDEXX Water DNA/RNA Magnetic Bead Kit and the IDEXX Water SARS-CoV-2 RT-PCR Test have been updated and improved since that date. Please refer to the IDEXX website for the most up to date procedures and test kits: https://www.idexx.com/en/water/water-productsservices/water-sars-cov-2-rt-pcr-test/ IDEXX has validated both the procedures below and updated procedures to provide consistent results in wastewater. The concentration protocol below is provided as an example. The IDEXX Water extraction and PCR test kits can also be used with other concentration or sample preparation protocols.Contact IDEXX Technical Support for more information (1 800 321 0207).

• All work will be performed in a BSL-2 laboratory in accordance with recommended procedures for handling and processing of wastewater samples associated with SARS- CoV • All centrifugation steps will be performed using sealed rotors or buckets with sealed safety cups. Rotors and buckets will be loaded and unloaded only in a biosafety cabinet.• Upon receipt, the exterior surfaces of sample containers will be decontaminated with 70% isopropanol and exposed to short-wave (UV-C) light using controlled contact and exposure times as detailed below.• Liquid waste will be decontaminated by dilution with bleach to a final concentration of 10% and incubated at ambient temperature for ≥ 60 minutes before disposal.

Procedural Notes• Concentration is performed according to the instructions in the Water SARS-CoV-2 RT-PCR Kit product insert (available here: https://www.idexx.com/files/product-insert-water-sarscov-2-rt-pcr-test.pdf), using the example procedure detailed below.• This procedure concentrates SARS-CoV-2 from 105 mL of wastewater.

• Samples will be stored at 2-8°C upon receipt.• Samples are maintained at cold temperatures near 4°C throughput the procedure using refrigerated centrifuge equipment and by minimizing handling time outside of the centrifuge.• Pasteurization is optional. In the WRF 5089 study, samples will be processed with and without pasteurization. • Pasteurization will be performed on the same day the sample is received at the laboratory, if possible.Pasteurization:1. Decontaminate exterior surface of container with 70% isopropanol, using a wet contact time of ≥ 5 minutes. Expose container surface to short-wave (UV-C) light using controlled exposure time and distance between container and light source. 2. Incubate sample in a 60 ±1°C water bath for 1.5 hours, mixing once during incubation. 3. Cool sample to 2-8°C before proceeding with concentration. Sample may be stored overnight at 2-8°C.Concentration:1. Mix sample well, then add 35 ±1 mL to each of three (3) empty 50 mL centrifuge tubes.2. Centrifuge all three tubes at 4,700 RCF for 30 minutes at 4 ±1°C in a swinging bucket rotor. Use little or no braking force to prevent the bacterial pellet from being disturbed. 3. Add 3.5 ±0.1 g PEG 8000 and 0.788 ±0.01 g NaCl into three (3) empty 50 mL centrifuge tubes. 4. Promptly and gently, remove centrifuge buckets from centrifuge. Carefully decant supernatant, smoothly and in one consistent motion, from each tube into a 50 mL tube containing PEG and NaCl to prevent the pellet from being disturbed. 5. Mix the tubes containing PEG and NaCl at ambient temperature until completely dissolved. 6. Open tubes carefully and decant liquid into a new 50 mL centrifuge tube. This step prevents leaks during centrifugation due to powder interference with the cap seal. 7. Mark a location near the bottom of the tube and orient to the outside of the rotor during centrifugation. This will aid the resuspension of viral pellets that are not clearly visible 8. Centrifuge at 12,000 RCF for 120 minutes at 4 ±1°C. Use little or no braking force to prevent the viral pellet from being disturbed. 9. Promptly and gently, remove rotor from centrifuge. Carefully decant and discard most of the supernatant from each tube. Decant smoothly in one consistent motion to prevent the pellet from being disturbed. It is not necessary to remove all liquid as the remainder will be removed in the next step. 10. Centrifuge at 12,000 RCF for 5 minutes at 4 ±1°C. Use little or no braking force to prevent the viral pellet from being disturbed. SOP 4S.2 11 . Promptly and gently, remove rotor from centrifuge. Use a pipette to carefully remove and discard the remaining supernatant from each tube. Do not contact or disturb pellet with pipet tip. 12. Use a pipette to transfer 0.4 mL nuclease-free water to one of the tubes containing a viral pellet. 13. Resuspend the viral pellet by repeatedly pipetting to rinse the inside surface of the tube around the expected location of the pellet. Rinse a wide area surrounding the expected pellet location to ensure all precipitated virus is recovered. Some of the resuspension liquid will adhere to the sides of the tube. This liquid will be recovered in the next step. 14. Flash spin the tube at 1,000 to 3,000 RCF to collect all the liquid at the bottom of the tube. 15 . Pipette up and down several times to homogenize the concentrate, then transfer the entire volume to the second tube containing a viral pellet. Repeat steps 13 and 14 to resuspend the pellet and collect all the liquid. 16. Pipette up and down several times to homogenize the concentrate, then transfer the entire volume to the third tube containing a viral pellet. Repeat steps 13 and 14 to resuspend the pellet and collect all the liquid. 17. Transfer the recovered concentrate to a RNase free microtube. The volume should be approximately 0.4 mL 18. Proceed with extraction immediately, or store concentrate overnight at -25 to -15°C.

Procedural Notes:• Extraction of nucleic acids from the wastewater concentrate is performed according to the instructions in the Water DNA/RNA Magnetic Bead Kit product insert (available here: https://www.idexx.com/files/product-insert-water-dna-rna-magnetic-bead-kit.pdf) • A Positive Control and Negative Control will be included with each set of samples as described below in the "Quality Control Procedures" section below. 

Extraction control samples:The following control samples will be processed in parallel with each set of wastewater samples to be tested.• Extraction Positive Control (AccuPlex SARS-CoV-2 Verification Panel): An extraction control containing SARS-CoV-2 RNA will be extracted and tested along with each set of samples that are processed. The extraction positive control is used to demonstrate successful recovery of RNA during the extraction process and should test positive for the SARS CoV-2 target. The AccuPlex Verification Panel contains a recombinant virus engineered to harbor SARS-CoV-2 RNA sequences; this provides a full extraction control that requires lysis and recovery of single-stranded RNA from an encapsulated viral particle to produce a positive result. To perform the extraction positive control, 200 μL of the "Member 1" dilution provided in the Verification Panel is used as the sample during extraction. Results are interpreted according to the table in the "PCR Results Interpretation" section.• Extraction Negative Control (PCR Grade Water): A "no template" (negative) control containing no nucleic acids will be extracted and tested with each set of wastewater samples to verify the absence of nucleic acid contamination in the extraction reagents and materials. The Extraction Negative Control should give a negative result for the SARS CoV-2 target. To perform the extraction negative control, 200 μL of PCR Grade Water will be used as the sample during extraction.

Reaction Setup 

Water samples can be stored at 2-8 o C for up to 72 hours after collection.• If a delay in extraction is expected, store specimens at -70 o C or lower.• Extracted nucleic acid should be stored at -70 o C or lower.

1. Wastewater samples (approximately 50 ml) are filtered through a 0.22 micron filter.2. Approximately 36 mL of filtered wastewater is mixed with 12 mL of 50% (W/V) PEG, 1.2 M NaCl, mixed until solution is homogeneous, and incubated for at least 2 hours at 4 o C.3. Samples are then centrifuged at 12,000xg for 2 hr.4. Supernatant is removed and RNA is extracted from the pellet using Qiagen Viral RNA extraction kit following the manufactures instructions and eluted in a final volume of 60 microliters.

Store the samples at -20 oC if they can't be processed immediately.Prepare RT-qPCR Reactions 1) In the reagent set-up room clean bench, place RT-qPCR buffer, enzyme, and primer/probes on ice or cold-block. Keep cold during preparation and use.2) Mix buffer, enzyme, and primer/probes by inversion 5 times.3) Centrifuge reagents and primers/probes for 5 seconds to collect contents at the bottom of the tube, and then place the tube in a cold rack. 

This SOP describes the analysis by RT-qPCR of wastewater influent samples to detect RNA from the coronavirus SARS CoV-2 (which causes . Quantification of SARS CoV-2 RNA is accomplished through the N1/N2 assay (see Section 1.3 for details). Bovine coronavirus (BCoV) is used as a control to assess recovery from the entire process and is quantified through the BCoV control assay.

This document describes the steps related to sample processing, virus concentration, RNA extraction, and RT-qPCR: 

Recovery Control -A known amount of a recovery control can be spiked into the sample at desired points throughout the SOP in order to assess recovery (i.e. loss due to SOP steps). For any given spike point along the workflow, recovery results capture loss due to all downstream steps, though comparisons of replicates of the same sample spiked at different points may be used to assess loss due to individual steps. In this SOP, bovine coronavirus (BCoV) is used as a control. The amount of BCoV recovered at the end of the protocol is assessed using a relative qPCR assay targeting the transmembrane gene of BCoV (Decaro et al. 2008). Possible additional points for spiking BCoV include:• Before pasteurization and after pasteurization-a comparison of the relative amount of BCoV recovered in samples spiked before and after pasteurization indicates loss due to pasteurization. ○ On their own, samples spiked before pasteurization can be used to assess loss due to the entire process. ○ On their own, samples spiked after pasteurization can be used to assess loss due to all steps following pasteurization. SOP 4S.5H

Negative control -contains all reaction components for PCR except one No-template control -no template (i.e., extracted nucleic acids from standard or sample) added; nuclease-free water is added instead. Used to check contamination and primer dimer formation.Positive control -known amount of template added (e.g. 2019-nCoV_N_Positive Control); to check that the primers, probe, and reaction conditions worked and can detect the target. For this SOP, the 2019-nCoV_N_Positive Control serves as both a positive control and the standard.gBlock gene fragments (synthesized by IDT) -Double-stranded, linear, nucleic acids. In this protocol, a gBlock gene fragment of the BCoV transmembrane gene is used as a standard in qPCR for the BCoV control.Target -region of nucleic acid to be amplified (region that the primers "target"); can be a gene or part of a gene. In general, the BSC can be cleaned according to the steps outlined in Section 1.5. Note, however, that bleach is corrosive. DO NOT allow disinfectants with high concentrations of free chlorine to contact the stainless steel components of the biosafety cabinet for a long period of time. Free chlorine will corrode stainless steel after extended contact (Reference).• Wear appropriate PPE (gloves, lab coat, eye protection).

○ Allow the bleach to contact the work surface for a minimum of 10 minutes. ■ Wipe surfaces with the bleach solution.• When wiping down pipettes, do not allow the decontamination solution to come in contact with the gaskets or seals. ■ Wipe the area/equipment down with sterile/de-ionised water. Note:Wiping with water is important because bleach is corrosive and can cause damage over time if not properly removed. • Wipe surfaces down with a paper towel dampened with 70% ethanol.• Use the UV light in BSC to UV-sterilize pipettes and tube racks.○ Close the sash and turn on the UV light for 5 minutes. ○ Turn off the UV light and turn over pipettes and tube racks. ○ Close the sash and turn on the UV light for 5 additional minutes to sterilize the other side of the pipettes and racks. ○ Turn off the UV light • Discard and replace gloves.

After each sample use, rinse each Oak Ridge 50mL tube with diH20 before adding ~2mL of 10% bleach. Rinse the entire tube with bleach solution by inverting it 5 times. Leave at room temp to incubate for 10 minutes. Submerge lids in 10% bleach for 10 minutes Discard bleach and rinse tubes and lids at least 5 times with diH20. Dry tubes and lids at 55°C for 24 hours SOP 4S.5H 11 

Please refer to the safety data sheet (SDS), provided in the SDSs subfolder, for each reagent as well as equipment manuals for safe handling before use.Resource about chemical use in the biosafety cabinet: https://www.ehs.washington.edu/system/files/resources/ChemicalUseinBSC-final.pdf All lab personnel should wear appropriate PPE at all times (including gloves, lab coats, and goggles). Gloves should be changed frequently for safety and to prevent contamination of the reagents, samples, and assays.Safety warnings and precautions found here. All raw samples should be handled in the biosafety cabinet. (Additional safety guidelines will be established with DEP)• Most recent CDC biosafety requirements: https://www.cdc.gov/coronavirus/2019ncov/lab/lab-biosafety-guidelines.html#environmental • Disinfecting with Bleach • Disinfection after handling unpasteurized samples ○ EPA-approved disinfectants: https://www.epa.gov/pesticide-registration/list-ndisinfectants-use-against-sars-cov-2-covid-19 SOP 4S.5H

• Custom BCoV qPCR assay (shipped dry at room temperature) pre-mixed primers and probe In the previously decontaminated workstation designated for REACTION MIX PREP: ○ Confirm on the specifications sheet that the delivered assay contains 5.0 nm of Primer 1, 5.0 nm of Primer 2, and 2.5 nm of probe. ■ The mass of the primers/probe delivered is used to determine the volume in which to resuspend the pellet in the next step (1000 µL). If the IDT spec sheet indicates a different mass delivered, adjust the volume of nucleasefree water added to obtain 5 µM of each primer in the final stock, based on the equation provided in the "BCoV Reaction Mix" tab of the accompanying spreadsheet. ○ Using a P1000 pipette, add 1000 µL nuclease free water and gently vortex the primer/probe mix using a vortex mixer on low speed. Ensure that the pellet is completely resuspended. ○ Mix the primer/probe mix by inversion 5 times. ○ Centrifuge the primer/probe mix for 5 sec in a mini microcentrifuge then place on ice. ○ Aliquot the primer/probe mix in 1.5 mL LoBind tubes:■ Using a P100 pipette, divide into 16 separate 60 µL aliquots and label "BCoV primer/probe 60 µL" with the date and initials.• These aliquots contain enough primer/probe mix for a plate containing 13 samples, a NTC, and one standard curve (60 reactions). • Place these aliquots in a plastic freezer box labeled "BCoV primer/probe" and store at -20°C. ○ Aliquot the positive control in 1.5 mL LoBind tubes: ■ Using a P10 or P20 pipette, divide into 31 separate 8 µL aliquots and label "N_Std-stock 8 µL" with the date and initials.• These will be used for making standards for future plates (1 standard curve/aliquot). Note: when the standards are made, the contents of this tube will be diluted to make the first standard, so be sure to leave space on the tube to re-label as "STD 1" later on. • It is critical to include the date on the tube, as the stock concentration may vary for different shipments (see following section on Nanodrop: Standards Concentration Check).

• Place these aliquots in a plastic freezer box labeled "2019-nCoV_N_Positive Control Standard-stock" and store at -20°C. ■ Set aside one aliquot for concentration check with the Nanodrop spectrophotometer and log results in accompanying Excel Spreadsheet. ○ Store any remaining positive control in the "2019-nCoV_N_Positive Controlstock" plastic freezer box at -20°C.• BCoV Standard gBlocks® Gene Fragments (250 ng shipped dry at room temperature) In the previously decontaminated workstation designated for TEMPLATE PREP: ○ Confirm on the specifications sheet that the delivered assay contains close to 250 ng of standard. ○ Using a P100 pipette, add 100 µL nuclease free water and gently vortex the primer/probe mix on low speed using a vortex mixer. Ensure that the pellet is completely resuspended. ○ Vortex the positive control on low speed using a vortex mixer. ○ Spin down briefly with a mini microcentrifuge, and place on ice. ○ Aliquot the positive control in 1.5 mL LoBind tubes: ■ Using a P10 or P20 pipette, divide into 16 separate 6 µL aliquots and label "BCoV Std-stock 6 µL" with the date and initials.• These will be used for making standards for future plates (1 standard curve/aliquot). Note: when the standards are made, the contents of this tube will be diluted to make the first standard, so be sure to leave space on the tube to re-label as "STD 1" later on. • It is critical to include the date on the tube, as the stock concentration may vary for different shipments (see following section on Nanodrop: Standards Concentration Check). • Place these aliquots in a plastic freezer box labeled "BCoV Standard-stock" and store at -20°C. ■ Set aside one aliquot (any standard remaining after aliquots) for concentration check with the Nanodrop spectrophotometer and log results in the accompanying Excel Spreadsheet. ○ Store any remaining positive control in the "BCoV Standard-stock" plastic freezer box at -20°C.• Calf-Guard® Bovine Rota Coronavirus vaccine In the previously decontaminated biological safety cabinet: ○ Dissolve the vaccine in 1 mL of TE buffer. Label the container "BCoV Control Spike" with the date and indicate that TE buffer has been added. ○ Using a P100 pipette, divide the resuspended BCoV Control spike into 10 separate 100 µL aliquots in 1.5 mL LoBind tubes. Label each tube "BCoV Control Spike" with the date and initials. ○ These are single use aliquots. ○ Store the spike aliquots at -80°C in the dark, covered with foil or in a freezer box labeled "BCoV Control Spikes." SOP 4S.5H

Concentrations of the standard stocks shipped from IDT may vary. This step checks the stock concentration (in ng/µL) of standards using the Nanodrop Spectrophotometer. The "N1/N2 Plasmid Standard Log" and "BCoV Standard Log" tabs of the accompanying Excel Spreadsheet calculate and log the concentration in (copies/µL).Ensure that the Nanodrop is calibrated and ready to collect data. Detailed instructions for the calibration check can be found on page 7-2 of the Nandrop 2000/2000c user manual.• Using a P10 pipette, blank the Nanodrop with 2 µL of TE buffer. ○ Note: If you are checking the concentration of a standard diluted in nuclease-free water rather than the stock shipped directly from IDT, blank the Nanodrop with nuclease-free water instead. • Wipe the upper and lower pedestals using a dry kimwipe.• Obtain the aliquot of the standard set aside for the concentration check.○ Record the date written on the aliquot tube in the "Aliquot Date" column of the "N1/N2 Plasmid Standard Log" tab or "BCoV Standard Log" tab in the Excel spreadsheet. • Record duplicate measurements of the plasmid standard using 2 µL each time.○ Wipe the upper and lower pedestals using a dry kimwipe in between and after each measurement. • Enter the measured concentrations (ng/µL) in the "Measured Concentration" column of the "N1/N2 Plasmid Standard Log" tab or "BCoV Standard Log" tab in the Excel spreadsheet. The spreadsheet will automatically calculate the average concentration in ng/µL as well as the concentration in copies/µL based on the plasmid length. • In the biosafety cabinet, spray the outside of the sample containers with 70% ethanol to decontaminate. Wipe down the containers and ensure that they are dry before proceeding to the next step, but be careful not to wipe off any sample labels/markings. • Transfer 40 mL of each sample into a separate, labeled 50 mL conical tube.• For one of the samples, do the step above in duplicate. This duplicate to be handled in the same manner as the samples throughout the procedure. • Prepare a method blank by adding 40mL of DI water into a separate, labeled 50 mL conical tube. • Place all 50mL conical tubes in the dedicated 60°C water bath.• Wait until samples reach an internal temperature 60°C (around 30 minutes), then pasteurize samples for 60 minutes. Mix by inverting one time halfway. • After pasteurization, remove all tubes from the water bath and wipe away any remaining liquid outside of each conical tube. • Place all tubes in a room temperature water bath and then on ice until the internal temperature of the samples is 23°C ± 5°C. • FULL DECONTAMINATION of biosafety cabinet. 

• Centrifuge the samples at 5000 x g for 10 min at 4 °C with brake setting at 0.

Without disturbing the pellet, carefully transfer 40 mL of each sample supernatant to a Corning™ Disposable Vacuum Filter/Storage System (0.22 m filter) using a disposable vacuum filter system (Corning 431154). Attach disposable vacuum filter system to laboratory stationary vacuum line, or manifold connected to electric vacuum pump. Turn on vacuum line and filter until all liquid has passed through the filter. Transfer filtrate to previously bleach sterilized 50mL Nalgene Polycarbonate Oak Ridge tube (Thermo Fisher Scientific 31380050).

• Using an analytical balance, weigh out individual dishes/tubes of 0.9 g NaCl and 4.0 g PEG 8000 for each sample.In the biosafety cabinet:• Add 0.90 g of solid NaCl to each 40-mL liquid sample and mix through inversion.• Add 4.0 g of solid PEG to each tube and mix through inversion until PEG/NaCl has dissolved. • Shake until liquid sample and PEG mix is translucent.• Hold samples overnight in the refrigerator at 4 o C (for at least 16 hrs).

• Remove tubes from 4 o C refrigerator and transfer to centrifuge. • Prior to centrifugation, mark tube with black marker where the pellet is expected to precipitate (Note this will help determine pellet location when examining later). • Centrifuge the tubes at 12,000 x g for 120 minutes at 4 o C with no brake applied (setting for the brake is 0). The pellet may be invisible. • In the biosafety cabinet, remove the majority of supernatant by decanting.○ Pour supernatant carefully from the side of the tube opposite to the pellet. ○ Collect the supernatant in a liquids container as biohazardous waste for future autoclave. • Centrifuge tubes again at 12,000 x g for 5 minutes at 4 o C.• Remove final remaining liquid with a sterile glass Pasteur pipette.• FULL DECONTAMINATION of biosafety cabinet, centrifuge, and rotor. SOP 4S.5H 26 

The QIAamp Viral RNA Mini Kit is used. The protocol below is modified from the instructions provided by QIAgen for this kit. These changes affect (1) the lysis buffer mixture and (2) the tube transfers.Perform all steps in the biosafety cabinet. Extract RNA from liquid samples in the biosafety cabinet according to instructions provided for the QIAamp Viral RNA Mini Kit (Manual also available from Qiagen) Volume changes to lysis buffer mixture and tube transfers are noted below. 

See Appendix A for general guidelines for PCR.Maintain a record of where standards will be placed in the 96-well PCR plate using the provided "plate" tab of the qPCR set up spreadsheet. Also enter this information into the PCR instrument software.Ensure that the computer, software, and PCR instrument are on, connected, and functioning properly prior to starting. Real-time PCR run information and plate set-up should be entered and saved in the software before starting step 3.5 to ensure that the PCR can begin as At end of day: Ensure a FULL DECONTAMINATION of all workstations after use.

General data analysis guidelines Adapted from the TaqPathTM 1-Step RT-qPCR Master Mix, CG USER GUIDE:1. View the amplification plot, and modify as needed:a. Use the automatic settings for baseline and threshold values. b. Identify and work with the QAO to determine whether it is appropriate to remove outliers from the analysis. • Remove an aliquot of the BCoV Std-stock 6 µL from the -20°C freezer and thaw on ice. This aliquot will be diluted and used for the first standard. Strike through the label which reads "original stock" and label tube with "STD 1" with a lab pen or marker. ○ Record the date indicated on this aliquot. Enter this date in the appropriate cell of the "BCoV Standard Curve" tab of the accompanying spreadsheet. This date identifies the stock standard concentration based on the Nanodrop concentration check logged in the "BCoV Standard Log" tab. ■ After the date is entered, the spreadsheet will automatically update the standard curve information for the corresponding "BCoV Standard Curve" and "BCoV Plate" tabs. • Obtain a decontaminated microcentrifuge tube rack and five (5) 1.5 mL LoBind tubes and label the tubes "STD 2" -"STD 6." • Place the tube rack on ice.• Pipette 18 uL of nuclease-free water (using a P100 or P200 pipette) into each of the tubes, starting with STD 6, STD 5, STD 4, STD 3, STD 2 (note: the empty tubes are filled first to avoid contamination of all the tubes with the positive control plasmid already in the STD 1 tube). Close each tube immediately after adding water. • Pipette 18 µL of nuclease-free water into the STD1 tube containing 6 µL of positive control plasmid. Vortex using a vortex mixer, spin down briefly with a mini microcentrifuge, and place on ice. • Using a P10 pipette, transfer 2 µL of STD 1 to the STD 2 tube containing 18 µL of water, to make a 1 in 10 dilution. Vortex, spin down briefly, and place on ice.

• Using a P10 pipette and new tip, transfer 2 µL of STD 2 to the STD 3 tube containing 18 µL of water, to make a 1 in 10 dilution. Vortex, spin down briefly, and place in the tube rack. Perform a serial dilution by repeating this procedure according to Table 3 .5.1 to make all 6 standards. Be sure to use a new tip for each transfer and immediately vortex and spin down each new standard after it is made (Figure 3 .5.1). • Close the tubes and keep the standards on ice as they are made. 

All steps completed in the workstation designated for REACTION MIX PREP.• 

Carefully transfer the covered plate to the previously decontaminated workstation designated for TEMPLATE PREP.• Use a previously decontaminated P10 pipette to transfer nuclease-free water and standards (volumes indicated below) into the appropriate wells. While adding, pipette up and down three times to mix the template with the reaction mix in the well. Change tips after each addition. • Seal the reaction plate with optical adhesive film using the adhesive seal applicator (video instructions). • Centrifuge the plate briefly (<1500 rpm, 1 min, 4°C, based on recommendation forStepOnePlus calibration plates) to bring the contents to the bottom of the well and eliminate air bubbles. Proceed immediately to step 3.5.5. (Run of the real-time PCR instrument).

• Retrieve the plate from the centrifuge and load into the real-time PCR instrument, orienting the wells in the correct direction. • Check that the saved run has all the correct conditions and that the plate set-up is correct and saved. Real-time PCR run information and plate set-up should be entered and saved in the software before starting step 3.5 to ensure that the PCR can begin as soon as the plate has been prepared. Ideally, a template can be used to expedite this process. References for the StepOnePlus can be found in Appendix B.StepOnePlus Run Set-up "Amplification technologies such as PCR are sensitive to accidental introduction of PCR product from previous amplifications reactions. Incorrect results could occur if either the clinical specimen or the real-time reagents used in the amplification step become contaminated by accidental introduction of amplification product (amplicon). Workflow in the laboratory should proceed in a unidirectional manner.Maintain separate areas for assay setup and handling of nucleic acids.Always check the expiration date prior to use. Do not use expired reagent. Do not substitute or mix reagent from different kit lots or from other manufacturers.Change aerosol barrier pipette tips between all manual liquid transfers.During preparation of samples, compliance with good laboratory techniques is essential to minimize the risk of cross-contamination between samples, and the inadvertent introduction of nucleases into samples during and after the extraction procedure. Proper aseptic technique should always be used when working with nucleic acids.Maintain separate, dedicated equipment (e.g., pipettes, microcentrifuges) and supplies (e.g., microcentrifuge tubes, pipette tips) for assay setup and handling of extracted nucleic acids.Wear a clean lab coat and powder-free disposable gloves (not previously worn) when setting up assays.Change gloves between samples and whenever contamination is suspected.Keep reagent and reaction tubes capped or covered as much as possible.Primers, probes (including aliquots), and enzyme master mix must be thawed and maintained on cold block at all times during preparation and use.Work surfaces, pipettes, and centrifuges should be cleaned and decontaminated with cleaning products such as 10% bleach, "DNAZapTM" or "RNase AWAY®" to minimize risk of nucleic acid contamination. Residual bleach should be removed using 70% ethanol.RNA should be maintained on cold block or on ice during preparation and use to ensure stability.Dispose of unused kit reagents and human specimens according to local, state, and federal Regulations.

45 Protect fluorogenic probes from light.Primers, probes (including aliquots), and enzyme master mix must be thawed and kept on a cold block at all times during preparation and use.Do not refreeze probes. Controls and aliquots of controls must be thawed and kept on ice at all times during preparation and use."Taken directly from the TaqPathTM qPCR Master Mix, CG user guide:"When preparing samples for PCR or RT-PCR amplification:Wear clean gloves and a clean lab coat. Do not wear the same gloves and lab coat that you have previously used when handling amplified products or preparing samples. Change gloves if you suspect that they are contaminated.Maintain separate areas and dedicated equipment and supplies for:• Sample preparation and reaction setup.• Amplification and analysis of products.• Do not bring amplified products into the reaction setup area.• Open and close all sample tubes carefully. Avoid splashing or spraying samples.• Keep reactions and components capped as much as possible.• Use a positive-displacement pipettor or aerosol-resistant barrier pipette tips. Cross-reactivity note: OC43 assay will detect BCoV so both spikes should not be used simultaneously November 12, 2020f. Perform a recovery spin: i. Turn the concentrate cup upside down and place on top of the sample filter cup ii. Centrifuge inverted at 2,250 rpm (~1,000×g) for 1 minute at 10°C iii. Remove the device from the centrifuge iv. Remove the concentrate cup and transfer the recovered concentrate into a 2-mL microcentrifuge tube using a pipette 4. Record total filtrate volume and recovered concentrate volume 5. Freeze the concentrate or immediately proceed to nucleic acid extraction 6. Discard the Centricon filter device and sample bottle appropriately